Applications of Organic Probes for Imaging and Analysis of Different Cancer Cell Models by Guan, Hong
University of South Carolina
Scholar Commons
Theses and Dissertations
5-8-2015
Applications of Organic Probes for Imaging and
Analysis of Different Cancer Cell Models
Hong Guan
University of South Carolina - Columbia
Follow this and additional works at: https://scholarcommons.sc.edu/etd
Part of the Organic Chemistry Commons
This Open Access Dissertation is brought to you by Scholar Commons. It has been accepted for inclusion in Theses and Dissertations by an authorized
administrator of Scholar Commons. For more information, please contact dillarda@mailbox.sc.edu.
Recommended Citation
Guan, H.(2015). Applications of Organic Probes for Imaging and Analysis of Different Cancer Cell Models. (Doctoral dissertation).
Retrieved from https://scholarcommons.sc.edu/etd/3068
APPLICATIONS OF ORGANIC PROBES FOR IMAGING AND ANALYSIS OF 
DIFFERENT CANCER CELL MODELS 
 
by 
 
Hong Guan 
 
Bachelor of Science 
Tsinghua University, 2005 
 
Master of Science 
Medical College of Wisconsin, 2009 
 
 
 
Submitted in Partial Fulfillment of the Requirements 
 
For the Degree of Doctor of Philosophy in 
 
Chemistry 
 
College of Arts and Sciences 
 
University of South Carolina 
 
2015 
 
 
Accepted by: 
 
Qian Wang, Major Professor 
 
John H. Dawson, Committee Member 
 
Stephen L. Morgan, Committee Member 
 
Guiren Wang, Committee Member 
 
Lacy Ford, Vice Provost and Dean of Graduate Studies
ii 
© Copyright by Hong Guan, 2015 
All Rights Reserved. 
  
iii 
Dedication 
 
 This dissertation is dedicated to my loving, optimistic and supportive husband, 
my cute smart little boy and girl, and to my always supportive and faithful parents and 
brother. Your love and positive energy have provided the wings to fly higher.  
  
iv 
Acknowledgements 
 
 Great appreciation and sincere thanks for the suggestions and support are 
present here to the following persons who have made this dissertation possible. 
 Dr. Qian Wang, my advisor and my life guider, his suggestions and 
foresights have been beneficial not only to my research, but also to my life and my 
future career. I am deeply indebted to his stimulating motivation and valuable ideas 
which help to make this work possible. His patience and kindness have been with 
me for each moment in the life. His caring and support are also extended to my 
family. He is a great supervisor for us in every field. 
 Dr. Xinrui Duan, I would like to thank him for his innovation and patience 
with me. He has taught me how to think critically and scientifically. His curiosity 
and enthusiasm in science lead me to enjoy every day working.  
 I would like to thank my fellow lab members for their valuable comments 
and suggestions, including Dr. Honglin Li, Dr. Jun Hu and Dr. Yuping Shan for 
sharing their expertise in organic chemistry and analysis chemistry, as well as their 
constructive discussion and valuable comments on my research. Thanks to my lab 
member Xia Zhao who has been with me and engaged me with scientific talking.  
 Dr. Chang-UK Lim and Dr. Udai Singh, their helps in performing and 
analysis of the flow cytometry assay in Chapter 1 and Chapter 4 are greatly 
v 
appreciated. Their instructions and suggestions on cell analysis and sorting provided me 
invaluable experience.  
I greatly appreciate helps and suggestions from fellows of Dr. Hexin Chen’s lab, 
including graduate student Yogin Patel, and Dr. Shou Liu. Their suggestions and help in 
cell culturing and signaling pathway analysis in Chapter 1, 2 and 4 have expanded my 
knowledge.  
I also owe thanks to Dr. Franklin G. Berger, Dr. Daping Fan for their helps on 
searching for proper cell lines. I would like to extend my gratitude to Dr. Andrew 
Greytak and Yi Shen for their collaboration in synthesis DBCO-Quantum dots in Chapter 
3. 
Great gratitude and sincere thanks to Dr. John H. Dawson, Dr. Stephen L. Morgan, 
Dr. Guiren Wang, my committee members, for reviewing and evaluating this dissertation 
and their invaluable suggestions and kind help throughout my graduate study. 
 I would like to thank my family and friends for their endless love and supports. 
My classmates and friends from University of South Carolina, especially Jie Gao’s 
family and Chao Li, they always stand by me and are willing to help. I would like to 
extend my appreciation to my friends Yuwei Kan and Xiaofang Zhang, for being my best 
friends and sharing their life with me. My parents in law and my sister in law have been 
with me for each happy moment. Their encouragement and good wishes are meaningful 
to me.  
I owe great appreciation and love to my special one, my husband Xiaoguang Ma, for 
his sweet understanding, supports and love. My little ones, Rachel and Tyler, I am so 
vi 
grateful to have you two in my life. You cute faces are source of my happiness and 
strength. 
Special thanks to my brother for sending his love over the phone. His love has 
securely protected me. Lastly, I would like to express my enormous thanks to my 
dear parents for their dedication, their hard working and their endless love. They are 
my source of strength, wisdom and inspiration. I am forever grateful for being their 
daughter. 
  
vii 
Abstract 
 
Novel techniques for better studying cancer cell behavior and progression are 
extremely important. Our lab is interested in synthesizing specifically designed organic 
reagents and applying them in the studies of cancers. In this dissertation, we used organic 
probes to investigate cancer cells in the following topics: determination of amino acid 
concentration in different types of cancers, tumor toxicity of organic probes towards 
HER2 positive breast cancer cells, glycoproteins identification in breast cancer cells and 
development of enzyme activity assay for colon cancer cells.  
The first chapter was focused on the determination of cysteine/homocysteine 
concentrations using turn-on sensors in cancer cells. Traditional methods such as HPLC 
are time consuming and cumbersome. DCP family probes were synthesized by our group 
previously, of which three probes reacted with cysteine/homocysteine specifically. To 
test the reactivity, the sensors were reacted with different substrates, including amino 
acid, nucleotides and proteins. All three sensors showed great selectivity towards cysteine 
and homocysteine. We confirmed the correlation between fluorescence intensity and 
cysteine concentration. Then liver cancer cell model which was previously reported with 
different intracellular cysteine concentration was used to test the sensitivity of sensor 2 
inside live cells. The staining results from the liver cancer cells pretreated with 400 μM 
of cysteine showed higher intensity of fluorescence than the cells pretreated with 0 μM.  
viii 
To study cysteine/homocysteine concentration in breast cancer cells, we used sensor 
2 to stain genetic modified breast cell line MCF10A Vector and MCF10A HER2, which 
could mimic normal breast cells and breast cancer cells. MCF10A HER2 had higher 
cysteine/homocysteine level than MCF10A Vector.  
Besides being good fluorescent probes, DCP family probes may also work as anti-
tumor drugs. To study the toxicity of DCP family probes, we have performed cell 
viability assay to screen possible probes targeting the breast cancer marker HER2 in 
Chapter 2. Several probes were selected and the HER2 downstream signaling pathways 
were further studied. It was found that sensor 3 may be further modified for HER2 
specific drugs to treat breast cancer.  
In Chapter 3, we used bioorthoganol probes and correlating reporters to develop 
protocols for cell imaging and enrichment of glycoproteins. Using two different 
fluorescent reporters, we addressed the total glycosylation level as well as cell surface 
specific glycosylation in three different breast cell lines. We also confirmed that breast 
cancer cells had elevated the level of glycosylation compared to the normal breast cells in 
this chapter. To enrich glycoproteins, our lab modified a silicone bead with disulfide 
bond and triple bond at the end of surface chain. The triple bond could react with azide 
and be used to fish labeled proteins while the disulfide bond could be cleaved to release 
the proteins after enrichment. Using this probe, we tried different methods for 
glycoprotein purification. Unfortunately, we were not able to develop a protocol to enrich 
glycoproteins with these beads. 
ix 
In the last Chapter, we moved to the enzyme activity detection in colon cancer cell 
line. A fluorescent sensor named RSAAA was synthesized specifically targeting on 
mitochondria and might be worked potentially as substrate for aldehyde dehydrogenase 2 
(ALDH2). We tested the efficiency of this sensor working as substrate for ALDH2. 
Based on the results, we developed a protocol to stain cells and isolated populations with 
different ALDH2 activity. To study the role of ALDH2 in cancer stemness, ALDH2 high 
and ALDH2 low cell populations were isolated using the protocol set up in this chapter. 
The tumorigenicity of two populations was studied to identify the enrichment of cancer 
stem cells. In HCT15, ALDH2 high cells had more cancer stem cell population and were 
more malignant compared to the ALDH2 low population. 
Specific designed probes could be powerful tools in the study of biological progress. 
We have devoted to the application of multiple probes to better understand and study 
cancer cells. Good communications between chemistry and biology help to support the 
translation from basic organic chemistry to the applications in biological fields. The 
emerging field of studies would be greatly appreciated in the development of new 
methods for biological processes.    
x 
Table of Contents 
 
Dedication .......................................................................................................................... iii 
Acknowledgements ............................................................................................................ iv 
Abstract ............................................................................................................................. vii 
List of Tables .................................................................................................................... xii 
List of Scheme ................................................................................................................. xiii 
List of Figures .................................................................................................................. xiv 
List of Abbreviations ....................................................................................................... xiv 
CHAPTER 1 Highly Selective Fluorescence Turn-on Sensors for Cysteine/Homocysteine 
for Live Cell Imaging .......................................................................................................... 1 
1.1 Introduction ........................................................................................................... 1 
1.2 Results and Discussion .......................................................................................... 9 
1.3 Conclusion ........................................................................................................... 24 
1.4 Experimental Section .......................................................................................... 25 
CHAPTER 2 Cell Toxicity of DCP Family Probes .......................................................... 28 
2.1 Introduction ......................................................................................................... 28 
2.2 Results and Discussion ........................................................................................ 29 
2.3 Conclusion ........................................................................................................... 36 
2.4 Experimental Section .......................................................................................... 37 
CHAPTER 3 Surface Glycan Localization and Purification ............................................ 39 
3.1 Introduction ......................................................................................................... 39 
3.2 Results and Discussion ........................................................................................ 48 
3.3 Conclusion ........................................................................................................... 62 
3.4 Experimental Section .......................................................................................... 66 
xi 
CHAPTER 4 Assessment of Aldehyde Dehydrogenase 2 (ALDH2) in Live Cells ......... 70 
4.1 Introduction ......................................................................................................... 70 
4.2 Results and Discussion ........................................................................................ 76 
4.3 Conclusion ........................................................................................................... 95 
4.4 Experimental Section .......................................................................................... 96 
REFERENCES .................................................................................................................... 102 
  
xii 
List of Tables 
 
Table 3.1. Buffers used in enrichment of glycoprotein with Si-beads .............................. 59 
Table 4.1. Human ALDH family proteins ........................................................................ 71 
Table 4.2. Primers of cancer stem cell markers .............................................................. 101 
 
xiii 
List of Scheme 
 
Scheme 1.1. Proposed mechanism of the oxidative SNArH and the following SNAripso 
reaction between sensor 1 and cysteine ............................................................................ 10 
 
 
 
xiv 
List of Figures 
 
Figure 1.1. Structures of thiol containing molecules and fluorescence sensors. ................ 2 
Figure 1.2. Schematic illustration of the cysteine metabolism pathways. .......................... 3 
Figure 1.3. HER2 signaling pathway. ................................................................................. 8 
Figure 1.4. Absorption (a) and fluorescence (b) spectra changes of 20 μM sensor 1 in 
CH3CN from 0 to 80 min upon addition of 100 μM cysteamine. ..................................... 11 
Figure 1.5. Fluorescence selectivity of cysteine sensor 1-3. ............................................. 14 
Figure 1.6. Quantification of cysteine in vitro. ................................................................. 15 
Figure 1.7. Fluorescent images (a, c) and overlay image with bright field (b, d) of 
HCT116 cell lines stained with 50 µM sensor 1 (upper level) and sensor 2 (lower level) 
for 0.5 h. ............................................................................................................................ 19 
Figure 1.8. Fluorescence (a-c, d-g) and bright field images (d, h) of live Hepg2/C3A. ... 20 
Figure 1.9. Sensor 2 indicated intracellular cysteine concentration in live cells. ............. 21 
Figure 1.10. Sensor 2 indicated intracellular cysteine concentration in live cells. ........... 22 
Figure 2.1. Structure of DCP and its derivatives tested in our study. ............................... 30 
Figure 2.2. Toxicity of DCP family probes in different breast cell lines. ......................... 32 
Figure 2.3. HER2 activation upon treating with DCP derivatives. ................................... 34 
Figure 2.4. Cell signaling targeted by DCP candidates. . ................................................. 35 
Figure 3.1. Different type of glycosylation. ...................................................................... 40 
Figure 3.2. Schematic figure of protocol for glycoprotein purification using azide-alkyne 
cycloaddition reaction. ...................................................................................................... 42 
Figure 3.3. Bioorthogonal reactions for proteins labeling. . ............................................. 44 
Figure 3.4. Structures of bioorthogonal chemical reporter for glycosylation. .................. 46 
xv 
Figure 3.5. Structures of fluorescent probes for labeled glycoproteins. . ......................... 49 
Figure 3.6. The schematic illustration of metabolic labeling and detection of 
glycoproteins with fluorescent probes. . ........................................................................... 50 
Figure 3.7. Staining of glycoprotein using DBCO-FL. .................................................... 53 
Figure 3.8. Staining of glycoprotein using DBCO-FL. .................................................... 54 
Figure 3.9. Staining of glycoprotein using DBCO-QT. .................................................... 56 
Figure 3.10. Schematic pictures to show the synthesis and characterization of Si-beads. 57 
Figure 3.11. Stability of S-S bonds in buffer 7. ................................................................ 58 
Figure 3.12. Purification control for the enrichment of glycoproteins. . .......................... 61 
Figure 3.13. Enrichment of glycosylated protein using Si-Alkyne beads: choice of lysis 
buffer. ................................................................................................................................ 63 
Figure 3.14. Enrichment of glycosylated protein using Si beads-choice of lysis buffer. . 64 
Figure 3.15. Enrichment of glycoprotein using Si beads-choice of protein releasing 
methods. ............................................................................................................................ 65 
Figure 4.1. Cancer stem cell models. ................................................................................ 73 
Figure 4.2. Aldefluor Assay. ............................................................................................. 74 
Figure 4.3. Structures of RSAAA and RSACOOH probes and their possible conversion 
pathways in cells. .............................................................................................................. 77 
Figure 4.4. Schematic mechanism of assay for ALDH2 activity.  ................................... 79 
Figure 4.5. Fluorescent property and cell retention of RSAAA and RSACOOH. . ......... 80 
Figure 4.6. Expression of ALDH2 in colon cancer cells. . ............................................... 82 
Figure 4.7. Enzyme activity of ALDH2 in different cell lines. . ...................................... 83 
Figure 4.8. Organic probes as ALDH2 substrates.  .......................................................... 84 
Figure 4.9. Inhibitors of ALDH2. . ................................................................................... 86 
Figure 4.10. Cell co-staining of organic probes and MitoTracker.  .................................. 87 
Figure 4.11. Cell co-staining of organic probes and LysoTracker. . ................................ 88 
Figure 4.12. Fluorescent intensity changed upon DEAB treatment. . .............................. 90 
xvi 
Figure 4.13. Gating of “Fluo Low”, “Fluo Medium” and “Fluo High” population. ........ 91 
Figure 4.14. Tumorgenicity of AAA sorting populations. ................................................ 93 
Figure 4.15. Cancer stem cell marker expression in AAA assay sorting populations. . ... 94 
 
  
xvii 
List of Abbreviations 
 
ABC .................................................................................................... ATP-binding cassette 
ALDH ........................................................................................... Aldehyde dehydrogenase 
BAA- ................................................................................................ BODIPY-aminoacetate 
BAAA .................................................................................... BODIPY-aminoacetaldehyde 
Bcl-2 ........................................................................................................ B-cell lymphoma 2 
CSC ............................................................................................................. Cancer stem cell 
Cys ...........................................................................................................................Cysteine 
DEAB .........................................................................................Diethylaminobenzaldehyde 
ELISA ....................................................................... Enzyme-linked immunosorbent assay 
ErbB ................................................................................. Epidermal growth factor receptor 
FBS ......................................................................................................... Fetal bovine serum 
FGFR................................................................................. Fibroblast growth factor receptor 
GAPDH ........................................................... Glyceraldehyde 3-phosphate dehydrogenase 
GCL.............................................................................................. Glutamate-cysteine ligase 
GSH..................................................................................................................... Glutathione 
Hcy ................................................................................................................. Homocysteine 
HER2................................................................. Human epidermal growth factor receptor 2 
HPLC .................................................................. High performance liquid chromatography 
Mcl-1 ............................................................................... Myeloid cell leukemia sequence-1 
PBS .............................................................................................. Phosphate buffered saline 
QRT-PCR .............................. Quantitative reverse transcription polymerase chain reaction 
1 
CHAPTER 1 Highly Selective Fluorescence Turn-on Sensors for 
Cysteine/Homocysteine for Live Cell Imaging 
 
1.1 Introduction 
1.1.1 The concentrations of thiol containing molecules are tightly controlled in cells 
There are many different thiol containing molecules in cells, including cysteine, 
homocysteine and glutathione (Fig. 1.1.a), which play essential roles in human 
physiology [1]. 
Cysteine (Cys) is a sulfur-containing amino acid that can be endogenously 
synthesized in human cells. The cysteine metabolism is showed in Fig. 1.2. Besides 
supporting protein synthesis, it is also the precursor for many biomolecules like 
glutathione, hypotaurine, taurine and inorganic sulfates [2]. The concentration of 
cysteine is tightly controlled in cells. While low cysteine levels might be associated 
with cardiovascular disease [3] and hematopoiesis decrease [4], high concentration 
of cysteine was toxic to cells. For example, high levels of intracellular cysteine 
could induce DNA damage by driving the Fenton reaction [5]. In addition, high 
plasma concentration of cysteine was associated with development of rheumatoid 
arthritis [6], Parkinson’s disease [7], Alzheimer disease [8].  
Homocysteine (Hcy) is another sulfur-containing amino acid. Compared to 
cysteine (193 µM), homocysteine (9.3 µM) is almost negligible in cells [9]. Similar 
as Cys, Hcy is a risk factor for many diseases, including cardiovascular [10] and
2 
. 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Structures of thiol containing molecules and fluorescence sensors. a) 
Structures of cysteine, homocysteine and glutathione. b) Structures of three fluorescence 
turn-on sensors used in this research. 
 
 
 
 
 
  
a) 
b) 
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Figure 1.2. Schematic illustration of the cysteine metabolism pathways [2, 11]. Cysteine 
can be synthesized from homocysteine and serine and it is the precursor for glutathione. 
Most of cysteine contributed for the protein synthesis. At each step, circle, rectangle and 
tricycle are used to stand for enzymatic control, inhibitor and enhancer, respectively. 
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Alzheimer’s disease [12]. Furthermore, total homocysteine concentration in plasma is 
related to birth defects and cognitive impairment in old people [13]. 
Glutathione (GSH) is the most abundant intracellular nonprotein-thiol (1.0-15.0 mM 
[14, 15]). It plays a pivotal role in maintaining a reducing environment in cells [16], 
acting as the redox regulator [17] and regulating the expression of different genes [18, 
19]. A redox homeostasis exists between sulfhydryl and disulfide forms for GSH [19]. 
Glutathione has also been reported to be involved in many diseases, including cancer 
[20], Alzheimer’s [21], and cardiovascular disease [22, 23]. 
Cysteine, homocysteine and glutathione metabolisms are closely correlated as 
shown in Fig. 1.2. For example, homocysteine is the precursor of cysteine [24], while 
cysteine is the precursor for the synthesis of glutathione and the rate determine reagent 
[25]. The enzyme, glutamate-cysteine ligase (GCL), catalyzes the synthesis of GSH from 
cysteine and glutamate [26]. It has been known that the Km of GCL from rat liver is 0.1 
mmol/L, which makes glutathione synthesis extremely sensitive to the intracellular 
cysteine concentration. This process is reversible when cysteine concentration is low [2]. 
The relations between these three thiol-containing molecules imply important roles of 
cysteine in disease development, progression and treatment [10, 12, 27-29].  
 
1.1.2 Cysteine concentration changes during diseases development 
Changes of intracellular and extracellular cysteine concentrations could both work 
as signals for cellular responses such as gene expression, protein synthesis and oxidative 
stress relief [25, 30]. Recent study had demonstrated that cysteine availability inside cells 
could control the thiolation of tRNA to regulate protein translation and metabolism 
5 
homeostasis [31]. Several studies showed cysteine availability from neighbor cells 
was essential for cell survival and scavenge of oxidative stress [30, 32].  
Cysteine concentration can be modulated by the transportation [33, 34] and 
metabolism [2] of cysteine or cystine. Cystine is the oxidized form of cysteine. Once 
cystine is imported into cells, it will be reduced to cysteine in a short time [35]. 
Mutations of key genes in cysteine metabolism pathways were correlated with 
abnormal cysteine concentration [30], which might be correlated with disease 
development and progression. For example, mice with a knockout in EAAC gene, 
which was known to be cysteine transporter in central neuron system, would 
develop a mental retardation syndrome similar to Parkinson disease [36]. Similarly, 
silencing of cystathionine -lyase led to lower cysteine concentration and mediated 
neuro-degeneration in Huntington’s disease mouse model [37].  
Because neurodegenerative diseases such as Parkinson disease had a low 
glutathione concentration in the plasma [38], it was difficult to track disease 
progression using glutathione sensor. In this case, the intracellular level of cysteine 
should provide information about signal transduction, nutrition availability and anti-
oxidant effect during disease progression.  
 
1.1.3 Methods to determine cellular cysteine concentration 
Several methods have been developed for the measurement of cysteine 
concentration, including high performance liquid chromatography (HPLC) [39], 
capillary gas chromatography-mass spectrometry [40], capillary electrophoresis 
[41], colorimetric and fluorescence detection [42]. Most chromatography methods 
6 
are highly dependent on equipment and hard to be processed in high throughput within a 
short timeframe [43]. Thus great efforts have been contributed to the development of 
selective fluorescence probe for cysteine detection inside cells recently [44, 45].  
Tanaka et al. reported a fluorescence turn-on cysteine sensor in 2004 [44]. However, 
the dye had a maximum emission wavelength at 380 nm, which was not within the visible 
region and could not be tracked by a regular microscope. Another turn-on 
cysteine/homocysteine sensor was developed by Zhang et al. in 2007 to detect the 
intracellular cysteine/homocysteine concentration [45], nevertheless the feasibility of the 
usage of this dye in live cells staining was questionable.  
In 2014, Dr. Honglin Li from our lab published a paper to correct the structure of 
cysteine sensor that was reported in Zhang et al.’s paper [46]. Based on this corrected 
core structure, we synthesized a family of new probes with turn-on fluorescence property 
when reacting with cysteine and homocysteine. In this chapter, the application of these 
dyes to detect cysteine/homocysteine in live cells was presented. Since intracellular 
cysteine concentration was significantly higher than homocysteine [9, 47], we 
hypothesized that the fluorescent signals were predominantly from the reaction with 
cysteine. 
Cysteine/homocysteine staining protocols in live cells provided information about 
cysteine/homocysteine concentration and localization. We were really interested in the 
study of breast cancer, thus our methods were applied to determine cysteine 
concentration in breast cancer cell lines. 
7 
1.1.4 HER2 and breast cancer 
Breast cancer is one of the most common types of cancer and a major cause of 
cancer-related deaths in women [48]. Certain factors have been reported to influence 
prognosis of breast cancer, including size, histological type and grade of the primary 
tumor, lymph node involvement, status of estrogen and progesterone receptors and 
other biomarkers [49].  Of those markers, the human epidermal growth factor 
receptor 2 (HER2) is one of the well-studied ones. Overexpression and amplification 
of HER2 have been shown to be correlated with increased disease recurrence as well 
as poor prognosis [50, 51].  
HER2 is a member of the epidermal growth factor receptor (ErbB) [52]. The 
ErbB family includes four members of plasma membrane bound receptor tyrosine 
kinases [53]. All four members contain an extracellular ligand binding domain, a 
transmembrane domain and an intracellular domain [54]. HER2 could form 
heterodimers with any other three receptors [55], of which dimerization would 
induce the auto-phosphorylation of tyrosine residues within the intracellular 
domains and initiated various downstream signal pathways leading to cell survival 
and cell proliferation (Fig. 1.3). Since overexpression of HER2 occured in 15-30% 
of breast cancer, drugs targeting HER2 could be used as potential cancer treatment 
for HER2 positive patients [50, 51]. 
HER2 expression levels might be related to intracellular cysteine level. For 
example, it was reported that the expression of micro RNA miR-26b, which targeted 
a subunit of cystine transporter-SLC7A11 [56], was significantly reduced in HER2+ 
tumor specimens [57]. 
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Figure 1.3. HER2 signaling pathway. Adapted from “N. U. Lin, et. al. 2007 Clin Cancer 
Res” with copy right permission. 
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To study the correlation between HER2 expression and cysteine level, we used 
MCF10A cell lines which have been programmed to over express control vector or 
HER2 (denoted as MCF20A vector and MCF10A HER2). MCF10A cell line has 
low expression of HER2 [58] and does not introduce genetic interference from other 
oncogene mutations. Overexpression of HER2 can consistently activate cell survival 
and proliferation pathways, which lead to higher tumorigenicity of this breast 
epithelial cell line [58]. Thus, MCF10A vector and MCF10A HER2 cell lines could 
be used as models for normal breast cells and HER2+ breast cancer cells.  
 
1.2 Results and Discussion 
1.2.1 Design of fluorescence turn-on sensors 
As showed in Fig. 1.2, a series of fluorescent probes with 1-oxo-1H-phenalene-
2,3-dicarbonitrile core structure have been synthesized in our lab. A unique sensing 
mechanism was proposed for this type of sensors (Scheme 1.1): the intramolecular 
base promoted oxidative SNArH (nucleophilic substitutions of aromatic hydrogen) 
reaction combined with an intramolecular displacement SNAripso (nucleophilic 
aromatic substitution) of thiol group by amino groups (Scheme 1.1). All three 
sensors react quickly with thiols in the presence of base and much slower under 
neutral condition (unpublished data). The absorption spectrum and fluorescence 
spectrum of reaction were measured on Varian Cary Eclipse Fluorescence 
Spectrophotometer. The maximum absorption peak of sensor 1 was centered at 430 
nm (Fig. 1.4.a).  Upon reaction with simple thiol-containing compounds, the 
absorption peak shifted to 512 nm, while the peak further shifted to 574 nm 
10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.1. Proposed mechanism of the oxidative SNArH and the following SNAripso reaction between sensor 1 and cysteine 
  
1
0
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Figure 1.4. Absorption (a) and fluorescence (b) spectra changes of 20 μM sensor 1 in 
CH3CN from 0 to 80 min upon addition of 100 μM cysteamine. 
  
a) 
b) 
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when reacted with amino acid. The fluorescence spectrum of reaction products showed 
peaks centered at 582 nm for simple thiol and 592 nm for amino acid. Due to the lack of 
neighboring amino group, such rearrangement reaction would not take place when the 
probes reacted with GSH. Instead, the probes could only react slowly with GSH through 
a direct thiol-substitution reaction. Because sensors 1-3 nearly showed no fluorescence, 
their turn-on property (Fig 1.4.b) and peak shift of fluorescence allowed them to be good 
candidates for intracellular cysteine/homocysteine sensing. 
 
1.2.2 Sensing specificity for cysteine 
To test the specificity of these turn-on sensors, different substrates including amino 
acids, thiol containing molecules (GSH, N-acetyl cysteine), dNTP and protein (bovine 
serum albumin) were incubated with sensors for 2 hours to allow reactions processing in 
phosphate buffered saline (PBS)  (Fig. 1.5. a). The fluorescence was recorded on MDS 
SpectraMax M2 microplate reader in 96-well microtiter plates. The folds changes of 
fluorescence: (I-I0)/I0 (I: fluorescence intensity of indicated solution; I0: fluorescence 
intensity of background.) did not change for more than 1 for most substrates (at the range 
of -0.45 ~ 0.42). This indicated that all three sensors had comparable low backgrounds in 
fluorescence when were incubated with those substrates.  
Conversely, the fluorescent intensity of sensor 1 increased for 43.8 ± 6.6 times when 
incubated with cysteine. Around 3.7 ± 0.4 and 2.0 ± 0.2 fold increase in fluorescence was 
observed for sensor 2 and 3. The fluorescence “turn-on” fold was also observed when 
treating with homocysteine, but it was much less profound, i.e. 19.1 ± 0.5 folds increase 
for sensor 1, 1.8 ± 0.9 folds for sensor 2 and 0.75 ± 0.06 folds for sensor 3, respectively. 
13 
Although the sensitivity of sensor 1 was much higher than sensor 2 and 3 on the 
detection of cysteine/homocysteine, the standard deviation was also much bigger for 
sensor 1 (Fig. 1.5).  
The intracellular concentration of GSH was very high and around 1-10 mM 
[14, 15], while the intracellular concentration of cysteine was relatively low and 
around 50-200 µM [2, 47]. Although we had confirmed that the fluorescent signal 
was comparable to background when incubating the sensors with 50 µM GSH, it 
might not be the same when GSH concentration was within the intracellular range, 
which might be 200 fold higher. To identify the potential interference from high 
concentration GSH, we incubated those sensors with either 200 µM cysteine or 5 
mM GSH for 2 hours. The fluorescence signals for cysteine/GSH/background were: 
sensor 1 (267.5/19.6/4.2), sensor 2 (144.9/26.3/19.1) and sensor 3 (101.3/244.3/34), 
respectively (Fig. 1.5.b).  This result confirmed the feasibility of using these sensors 
for intracellular cysteine detection.  
 
1.2.3 Quantitation of cysteine in vitro 
Before using our designed sensors to quantify cysteine, the relationship 
between cysteine concentration and fluorescence intensity needed to be 
demonstrated. Titrations of cysteine concentration against fluorescence intensity 
were performed for all three sensors in DMEM and the standard curves were 
generated (Fig. 1.6.a). Three calibrations were quadratic with coefficients of 
determination (R2) value around 0.99. This reliable relation between fluorescent 
intensity and cysteine concentration supports sensor 1, 2 and 3’s possibility to  
14 
 
Figure 1.5. Fluorescence selectivity of cysteine sensor 1-3. a) Fluorescence intensity on 
different substrate in PBS. All substrate: 50 µM. Gly: Glycine; Ala: Alanine; Ser: Serine; 
Thr: Threonine; Cys: Cysteine; Val: Valine; Leu: Leucine; Ile: Isoleucine; Met: 
Methionine; Pro: Proline; Gln: Glutamine; His: Histidine; Lys: Lysine; Arg: Arginine; 
GSH: Glutathione; NAC: N-Acetylcysteine; Hcys: Homocysteine; Phe: Phenylalanine; 
Trp: Tryptophan; Asp: Aspartic Acid; Glu: Glutamic Acid; Asn: Asparagine; BSA: 
Bovine Serum Albumin; dNTP: deoxynucleotide; Cysti: Cystine. b) Selectivity of 
sensors to intracellular level cysteine (200 µM) over GSH (5 mM). Substrates were 
incubated with indicated sensors for 2 h and fluorescence was read on plate reading. 
Sensor concentration for a) and b): 1 (10 µM) 2 (10 µM), 3 (50 µM). 
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Figure 1.6. Quantification of cysteine in vitro. a) Standard curve of sensor 1 (black square), 2 (red circle) and 3 (blue triangle). The 
polynomial fit of each sensor was showed in red line. b) Quantification of cysteine in cell culture medium. Sensor concentration for a) 
and b): 1 (10 µM) 2 (10 µM), 3 (50 µM). * indicate p < 0.05.  
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quantify cysteine concentration. 
To evaluate the potential application of cysteine sensors in vitro, the concentration 
of cysteine in cancer cell conditional medium was measured using this method. 
Conditional medium from HEK293T, HCT15 and HCT116 were collected as described 
in the experimental section. The medium was incubated with sensors for 0.5 hour and the 
fluorescence was recorded. Cysteine concentrations in the medium were calculated from 
the calibration. As showed in Fig.1.6.b, the cysteine concentrations in all three cell 
culture mediums were around 10 µM measured by sensor 1 and around 25 µM by sensor 
3. The reading of concentration for three cell lines was different from sensor 2, i.e. 
HEK293T and HCT116 medium were 33.5 ± 3.1 µM and 39.4 ± 10.0 µM while HCT15 
was 12.1 ± 7.5 µM respectively. There was no cysteine but only cystine in prepared 
mediums for HEK293T, HCT116 and HCT15. While cells were cultured in those 
mediums, they could uptake cystine and converted it to cysteine, which were then 
released to the mediums and might be used by other cells. From this experiment we found 
all three cell types could uptake cystine and convert it to cysteine. The cysteine 
concentrations in cell conditional medium were around 40 µM and might be varied 
among cell lines.  
 
1.2.4 Cell compatibility of cysteine sensors 
After confirming the in vitro application of these sensors, the cell compatibility of 
those sensors for live cell imaging was investigated. Sensor 1 and 2 were used to stain the 
cells and confocal images were taken to track their fluorescence. Sensor 3 was not tested 
due to its nonspecific reaction with GSH of intracellular concentration.  
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As shown in Fig. 1.7, the staining of sensor 1 was much weaker and not evenly 
distributed. This might be attributed to the low solubility of sensor 1 in aqueous 
solutions. Sensor 2 showed a brighter fluorescence signal and the staining was 
evenly distributed among cells. Since Sensor 2 had better cell compatibility, it was 
used in the consequent live cell imaging studies. 
 
1.2.5 Localization of cysteine/homocysteine in live cells 
One advantage of our turn-on fluorescence sensors was the low background, by 
which the tracking of cysteine in cells was clearer and more reliable. Cysteine is 
distributed all over the cells with enrichment in certain organelles such as 
mitochondria and lysosomes for their specific functions inside cells [45, 59]. Sensor 
2 had shown an uneven intracellular cell staining. There were regions that had 
higher fluorescence signals (Fig. 1.8.c and Fig. 1.8.g). We found that those regions 
with higher fluorescence signals were co-localized with both MitoTracker Green and 
LysoTracker Green (Life Science). Since intracellular homocysteine is negligible 
compared to cysteine, the majority of the fluorescence signal can be attributed to the 
reaction with cysteine. Although we have not performed further experiments to 
study the local cysteine concentration changes inside cells, it will be extremely 
interesting to know the cysteine concentration in specific localizations i.e. 
mitochondria and lysosome under different stimuli, especially for cancer cells. 
These cells are usually under high oxidative stress [30], which results in higher 
cysteine concentration in those localizations. 
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1.2.6 Semi-quantitation of intracellular cysteine in live cells 
As shown in section 1.2.3, the fluorescence intensity after incubating with sensor 
was proportional to cysteine concentration. Because sensor 2 had excellent cell 
compatibility, it was possible to use sensor 2 to quantify the intracellular concentration of 
cysteine. The intracellular cysteine concentrations are known to be 150 µM [47]. Certain 
cell lines, such as Hepg2/C3A, exhibits 3-6 fold changes in cysteine concentration when 
cultured with different concentrations of cysteine in medium [11, 60]. We pretreated 
Hepg2/C3A and HCT116 for 24 hours with 0 or 400 µM of cysteine in the full culture 
medium before the cells were washed and incubated with sensor 2 for 0.5 hour. Confocal 
images and flow cytometry were performed to track the intracellular cysteine 
concentration. Images from confocal microscope (Fig. 1.9.a) showed much higher 
fluorescence intensity in cells treated with 400 µM cysteine, which was further confirmed 
by flow cytometry (Fig. 1.9.b). Approximately 1.7 folds increase in fluorescence signal 
(Fig. 1.9.c) was observed in both cell lines (results of HCT116 were showed in Fig. 1.10) 
for cells incubated with 400 µM cysteine. These staining results confirmed sensor 2’s 
function on specifically indicating intracellular cysteine in live cells.  
To further study the cysteine concentration in cancer cells, we chose two MCF10A 
derived cell lines: MCF10A vector and MCF10A HER2. Cells were incubated with 
sensor 2 for 0.5 hour and the fluorescence was tracked by confocal imaging and flow 
cytometry. The fluorescence staining (Fig. 1.11) was higher for MCF10A HER2 cells and 
flow cytometry results confirmed MCF10A HER2 had higher fluorescence intensity 
(7279) than MCF10A vector (4380). It indicated that breast cancer cells had higher 
cysteine concentration compared to normal cell lines.  
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Figure 1.7. Fluorescent images (a, c) and overlay image with bright field (b, d) of 
HCT116 cell lines stained with 50 µM sensor 1 (upper level) and sensor 2 (lower level) 
for 0.5 h. 
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Figure 1.8. Fluorescence (a-c, d-g) and bright field images (d, h) of live Hepg2/C3A. Upper: Hepg2/C3A was co-stained with 50 µM 
sensor 2 (red) and MitoTracker (green) for 0.5 h. Bottom: Hepg2/C3A was co-stained with 50 µM sensor 2 (red) and LisoTracker 
(green) for 0.5 h. 
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Figure 1.9. Sensor 2 indicated intracellular cysteine concentration in live cells. 
Hepg2/C3A were pretreated with different concentration of cysteine for 24 h and then 
stained with 50 µM sensor 2 for 0.5 h. a) Confocal images of Hepg2/C3A pretreated with 
0 or 400 µM Cysteine then stained with sensor 2 (scale bar: 10 µm). b) Flow cytometry 
of the Hepg2/C3A pretreated with 0 or 400 µM cysteine (yellow: 0 µM; red: 400 µM). c) 
Bar graphs showing the fluorescence quantification of the Hepg2/C3A treated with 0 or 
400 µM cysteine. 
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Figure 1.10. Sensor 2 indicated intracellular cysteine concentration in live cells. HCT116 
were pretreated with 0 or 400 µM cysteine cysteine for 24 h and then stained with 50 µM 
sensor 2 for 0.5 h. a) Flow cytometry of the HCT116 pretreated with 0 or 400 µM 
cysteine then stained with sensor 2 (yellow: 0 µM; red: 400 µM). b) Bar graphs showing 
the fluorescence quantification of the Hepg2/C3A treated with 0 or 400 µM cysteine. 
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Figure 1.11. Cysteine concentration in MCF10A Vector and MCF10 HER2 cell lines. a) 
Confocal images of MCF10A Vector and MCF10 HER2 cell lines stained with sensor 2 
(scale bar: 50 µm). b) Flow cytometry of the MCF10A Vector and MCF10 HER2 cell 
lines stained with sensor 2 (yellow: MCF10A Vector; green: MCF10 HER2). c) Bar 
graphs showing the fluorescence quantification of the flow cytometry. 
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1.3 Conclusion 
Cysteine, homocysteine and GSH are major thiol-containing biomolecules in 
cells. They play important roles in maintaining normal cell state. Homocysteine is the 
precursor to synthesis cysteine and cysteine works as precursor for GSH synthesis. 
Interferences of thiol metabolism either by mutation of key enzymes or transporters are 
proved to be correlated with many diseases, including cardiovascular diseases, cancer and 
neurodegenerative diseases. Current methods to measure thiol-containing molecules 
include chromatography and fluorescent sensors. Protocols that can specifically assess 
cysteine, homocysteine and GSH concentration in live cell are not well developed. 
Our lab has synthesized a series of sensors that can selectively detect 
cysteine/homocysteine. The reaction was proved to be an intramolecular base promoted 
oxidative SNArH (nucleophilic substitutions of aromatic hydrogen) reaction combined 
with intramolecular displacement (SNAripso) of thiol group by amino group. Three probes 
(1-3) all showed good selectivity towards cysteine/ homocysteine. Standard curves of 
three sensors from titration of cysteine fitted polynomial regression with R2 over 0.99.  
Sensor 1 and sensor 2 both could react with intracellular concentration of cysteine 
but not GSH. Thus, these two sensors were used for in vivo imaging of cysteine/ 
homocysteine. Because intracellular homocysteine concentration was significantly lower 
compared to cysteine concentration, fluorescence was mainly from the reaction with 
cysteine. 
Both dyes could enter the cells (perhaps by using diffusion mechanism). Sensor 2 
was chosen for its better water solubility and good cell staining results. Furthermore, we 
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demonstrated that sensor 2 could be used to semi-quantify the intracellular 
cysteine quantification using a hepatocellular carcinoma cell model. The live cell 
imaging not just provided the localization of cysteine but also illustrated a semi-
quantification of cysteine in live cells.  
We also confirmed that cysteine concentration was higher in HER2+ breast 
cancer cell line: MCF10A HER2 compared to the control cell line: MCF10A Vector. 
With sensors 1-3, we improved the study of changes of cysteine under different 
conditions or treatments, by which the changes of cysteine levels could be measured 
in the progressions of different diseases such as cancer, Parkinson’s disease and 
Alzheimer disease.  
 
1.4 Experimental Section 
1.4.1 Sensing selectivity test of three sensors 
Different substrates (50 µM each for final concentration) was added to 200 µL 
either PBS or DMEM with indicated concentration of sensors (sensors 1: 10 µM, 
sensor 2: 10 µM and sensor 3: 50 µM) in black 96 well plate with clear bottom 
(Greiner 655906). Solutions were incubated for 2 hours at room temperature. The 
fluorescence was recorded on a MDS SpectraMax M2 Microplate Reader with 
excitation at 560 nm and emission at 600 nm. 
 
1.4.2 Cysteine standard Curve 
Different concentrations of cysteine were added to 200 µL DMEM with 
indicated concentration of sensors (sensors 1: 10 µM, sensor 2: 10 µM and sensor 3: 
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50 µM) in black 96 well plate with clear bottom (Greiner 655906). Solutions were 
incubated for 2 hours at room temperature. The fluorescence was read on a MDS 
SpectraMax M2 Microplate Reader with excitation at 560 nm and emission at 600 nm. 
 
1.4.3 Cell Maintenance 
The Hepg2/C3A cell line was purchased from the American Type Culture 
Collection (Cat No: HB/8065). Cells were maintained in sulfur amino acid-free DMEM 
supplement with 10% fetal bovine serum, 2 mM glutamine, 1 mM sodium pyruvate, 0.1 
mM L-methionine, 0.3 mM cysteine and 1× MEM nonessential amino acid solution. The 
HCT116, MCF10A vector and MCF10A HER2 cell lines were from Prof. Hexin Chen 
(University of South Carolina, Department of Biology Science). The HCT15 cell line was 
from Prof. Franklin G. Berger (University of South Carolina, Center for Colon Cancer 
Research). The HEK293T cell line was from Dr. Daping Fan (University of South 
Carolina, Department of Biology and Anatomy). HCT116, HEK293T cells were 
maintained in DMEM-high glucose medium with 10% fetal bovine serum. HCT15 cells 
were maintained in RPMI1640 medium with 10% fetal bovine serum (FBS). The 
MCF10A Vector and MCF10A Her2 were maintained in DMEM:F12(1:1) medium with 
5% horse serum, 10 µg/mL insulin, 20 ng/mL EGF, 100 ng/mL cholera toxin, 0.5 µg/mL 
hydrocortisone. Cells were passed every 2-3 days on a (1:8) ratio. All cells were in a 
water-saturated atmosphere of 5% CO2 and 95% air at 37°C. 
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1.4.4 Cell culture medium collection 
To determine the cysteine concentration in different conditional medium, 1 × 
106 cells/well HEK293T, HCT15 and HCT116 were seeded in 6-well plates and 
allowed to adhere and grow overnight. The medium was then switched to DMEM 
medium without FBS and cultured for another 24 hours. The medium was collected, 
clarified by centrifugation and used immediately.  
 
1.4.5 Confocal imaging 
Confocal fluorescence imaging was performed with Olympus X81 fluorescence 
microscopy. Cells were incubated with sensors and (+/-)-Verapamil Hydrochloride 
(MP Biomedicals, Cat. No: 195545) for 0.5 hour at 37°C. Fluorescence imaging was 
performed after washing cells three times with PBS buffer. 
 
1.4.6 Flow cytometry 
Cellular cysteine levels were quantified by flow cytometric analysis. 2 × 105 
cells/well HepG2/C3A cells were seed on 6-well plates two days before flow 
cytometry. The condition cell mediums with different cysteine concentration were 
changed one day before flow cytometry. Cells were trypsinized and 1 × 106 cells 
were collected for each sample as indicated. After washing two times with Assay 
Buffer (PBS with 0.5% FBS and (+/-)-Verapamil Hydrochloride), cells were 
incubated with 50 µM sensor 2 for 0.5 hour at 37°C. The samples were washed once 
with Assay Buffer and re-suspended in 0.5 mL Assay Buffer. Stained cells were  
analyzed by BD LSRII flow cytometer. 
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CHAPTER 2 Cell Toxicity of DCP Family Probes 
 
2.1 Introduction 
2.1.1 DCP family may have potential cell toxicity towards cancer cells 
The DCP family of probes have been reported by Dr. Xuhong Qian’s group and his 
coworkers as a potential inhibitor for Fibroblast Growth Factor [61]. Using enzyme-
linked immunosorbent assay (ELISA), three compounds were found to be active in 
inhibiting the activation of the Fibroblast Growth Factor Receptor 1 (FGFR1). Cell 
studies also confirmed their function in anti-proliferation of tumor cells [61]. More 
papers on the DCP derivatives were published in 2011 and 2013 [62, 63]. Certain DCP 
analogues could specifically inhibit the activation of the B-Cell Lymphoma 2 (Bcl-2) and 
Myeloid Cell Leukemia Sequence 1 (Mcl-1), thus induced apoptosis in tumor cells [62, 
63]. 
Recently, we found the structures assigned in both Xuhong Qian and Zhichao Zhang 
groups’ papers were not correct [46]. Dr. Honglin Li from our group confirmed the core 
structures of the DCP family compounds as 1-oxo-1H-phenalene-2,3-dicarbonitrile. To 
further investigate the potential roles as antitumor agents for these molecules, a series of 
DCP derivatives were synthesized. The function of those analogues as antitumor drugs 
was discussed in this chapter. 
We used MCF10A cell lines that had been programmed to over express control 
vector and HER2 as models. The DCP family molecules were used to treat those cell 
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lines and the cell viability was tested. The related signaling pathways were also 
investigated in order to discover the target of those molecules. 
 
2.2 Results and Discussion 
2.2.1 Structure of DCP derivatives 
The DCP family probes were shown in Fig. 2.1. They share the same 1-oxo-
1H-phenalene-2,3-dicarbonitrile core structure, with different side chains. Previous 
studies from Dr. Qian’s lab showed molecules with thiol containing side chains at 
position 3 could inhibit tyrosine kinase activation, including FGFR1, FGFR3 and 
VEGFR1. As we known, receptor tyrosine kinases were highly conserved in their 
intracellular C-terminal, which was responsible for the kinase activity. We therefore 
hypothesized that DCP family derivatives, which may be an inhibitor of kinase 
activity, might also inhibit HER2 activation. To test this hypothesis, our lab 
modified the core structure at position 6 and position 9 of DCP with thiol-containing 
side chain, azide-containing side chain and nitro-containing side chain for screening 
the impact of derivatization of DCP on HER2 inhibition. 
 
2.2.2 Cytotoxicity of DCP and derivatives 
The treatment for HER2 positive breast cancer was by a monoclonal antibody 
(Trastuzumab) [64]. Other small molecules as HER2 tyrosine inhibitors also 
underwent active clinical trials for their advantages in synthesis and treatment [64]. 
To screen for HER2 specific drugs, we chose MCF10A cell lines which were 
consistently over-expressing either control vector or HER2, namely MCF10A Vector 
and MCF10A HER2 as shown in Chapter 1. The MCF10A control could be 
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                       Figure 2.1. Structure of DCP and its derivatives tested in our study. 
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considered as normal breast tissue model while the MCF10A HER2 cell line could be 
considered as HER2+ breast cancer model. We screened all molecules at 1 × 10-6 M or 1 
× 10-5 M for 24 hours using cell viability assay. 
The results of the cell viability assay were showed in Fig. 2.2. Star in the figure 
indicated a significant difference in viability between MCF10A control and HER2 
cell lines by student t test with 95% confidence interval. At 1 µM, all DCP probes 
did not show significant toxicity. None of them could kill more than 50% cells. At 
10 µM, several members like DCP8b, sensor 1 and sensor 3 showed over 50% 
toxicity towards MCF10A HER2 cell line. DCP8b killed 66.3% cells while sensor 1 
killed 94.8% cells and sensor 3 killed 85.3% cells. The student t test of viability 
between MCF10A vector and MCF10A HER2 groups indicated sensor 3 preferably 
killed MCF10A HER2 cell lines. Therefore, sensor 3 might be a good candidate for 
HER2 breast cancer treatment. Interestingly, DCP8a, which was only different from 
DCP8b by the position of side chain, was much less toxic than DCP8b.  
According to NCI anti-cancer drug screening procedures [65, 66] in cell lines, 
IC50 (the concentration of treatment to kill 50% cells) should be less than 1×10-4 M 
to be considered for further studies. Thus, DCP candidates that could kill more than 
50% MCF10A HER2 cells were chosen (50% cell viability was showed in red dash 
line) for later downstream signaling pathway studies.  
 
2.2.3 Signaling pathway targeted by drug candidates 
To study the possible signaling pathways affected by drug candidates, Western-
blots were performed to study the major cell signaling pathways in breast cancer 
cells. Cells were treated with DCP8a, DCP8b, sensor 1 and sensor 3 for 24 hours.  
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Figure 2.2. Toxicity of DCP family probes in different breast cell lines. a) The toxicity of 1 µM DCP family probes treatment. b) The 
toxicity of 10 µM DCP family probes treatment. Probes were incubated with cells for 24 h at indicated concentration. Star indicates 
significant difference in toxicity between MCF10A vector and MCF10A HER2 cell lines by student t test with a 95 confidence 
interval. The red dash line is the 50% cell viability line.  
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Cells were lysed and proteins were collected. Activation of ERK (Extracellular signal 
Regulated Kinases), Akt (Protein Kinase B), Caspase-3 (cysteine-dependent aspartate-
directed protease-3) and HER2 were probed by Western-blot with collaboration with Dr. 
Hexing Chen’s group, which showed DCP8b, sensor 1 and sensor 3 led to less activation 
of HER2 (Fig. 2.3). This indicated that these molecules might interfere with HER2 
activation. As comparison, DCP8a did not affect the activation of HER2 at all. 
As shown in Chapter 1 (Fig. 1.3), there were mainly two pathways for the 
downstream activation of HER2. One was the ERK pathway that led to cell 
proliferation and the other was the Akt pathway that helped cell survival and 
protects from apoptosis. Thus inhibition of ERK might lead to abolishment of 
proliferation, while the inactivation of Akt might lead to the activation of Caspase-3. 
As Caspase-3 was a member of caspase family, this might lead to programmed cell 
death (apoptosis) [67]. The results from the down-stream signaling pathway (Fig. 
2.4) showed that sensor 3 might achieve its specific toxicity towards HER2 cell line 
by inactivation of ERK and activation of Caspase-3.  
DCP8b seemed to induce the inactivation of ERK and slight activation of 
Caspase-3.This might explain the toxicity of DCP8b by inhibiting cell proliferation 
and activating apoptosis. Both DCP8a and DCP8b inactivated Akt, but DCP8a did 
not affect the other two pathways. The differences in toxicity and downstream 
signaling pathway might be caused by the different structures of DCP8a and DCP8b, 
or DCP8a and DCP8b might interact with different targets in the cells. It will be 
interesting to study the specific binding targets of each probe in the future. Sensor 1 
did not affect Akt, ERK and Caspase-3 activation. The toxicity of this  
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Figure 2.3. HER2 activation upon treating with DCP derivatives. Western-blot for total 
HER2 and p-HER2 showed that sensor 1, sensor 3 and DCP8b can inhibit the activation 
of HER. 
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Figure 2.4. Cell signaling targeted by DCP candidates. The downstream signaling of 
HER2 were probes in Western-blot. p-ERK, p-Akt and Caspase-3 pathways were assayed 
to address the toxicity effect. 
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molecule to Vector and HER2 cells lines might be attributed to some other pathways. 
 
2.3 Conclusion 
The core structure of DCP has been reported to be a good candidate as an anticancer 
drug. Our lab had successfully synthesized a series of DCP derivatives. To assess those 
probes’ toxicity on cancer, we chose a specialized cell model for breast cancer. MCF10A 
either overexpressing control vector or HER2 (i.e. MCF10A Vector and MCF10A HER2) 
were employed in our study to mimic normal breast tissue and HER2+ cancer. Using 
these two cell lines, we successfully screened the DCP derivatives and identified four 
candidates that have different toxic property: DCP8a, DCP8b, sensor 1 and sensor 3.  The 
results showed sensor 3 had higher toxic effect on MCF10A HER2 cell lines.  
To study the signaling pathway in those treatment groups, we collaborated with Dr. 
Hexing Chen’s lab. Western-blots were performed to probe HER2 and its related 
pathways. It has been found that Sensor 3 treatment group significantly decreased HER2 
activation. This indicated the specificity of toxic towards the HER2 cell line might be due 
to the inhibition of HER2. The ERK activation was also decreased, which indicated an 
important role of Sensor 3 on ERK activation. Caspase-3 was activated upon Sensor 3 
treatment, which meant the apoptosis pathway was also activated in Sensor 3 treatment 
group. This study further confirmed that Sensor 3 specific toxicity on HER2+ cell line 
might be through the inhibition of proliferation pathway as well as the activation of 
apoptosis pathway. 
DCP8a is only different from DCP8b by the position of side chain. However, the 
toxic properties on cell lines were completely different. DCP8a did not have toxicity 
while DCP8b was pretty toxic to all cell lines, which implied special interactions between 
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DCP8b and targets. The signaling pathways of DCP8a and DCP8b treated cells were 
also different. DCP8b inactivated ERK and slightly activated Caspase-3, while 
DCP8a only slightly inactivated pAkt. This specific toxicities might be used for 
better structure designs of organic probes for HER2+ breast cancer drug. 
 
2.4 Experimental Section 
2.4.1 Cell viability assay 
The two MCF10A cell lines were seeded in 96-well plates (5 × 104 cells/mL, 
100 µL/well). After seeding, cells were allowed to adhere and grow overnight before 
the addition of DCP family probes. DCP family reagents were added to the culture 
medium of MCF10A and cells were incubated for 21 hours. The CellTiter-Blue 
(G8080) from Promega (10 µL) was added to the medium (100 µL). Cells were 
continuously incubated for another 3 hours according to the manual. Cell viability 
was determined using a Spectra Max M2 Plate Reader by monitoring the absorption 
at 595 nm. 
 
2.4.2 Western blots analysis 
Cell lysates were prepared and equal amounts of proteins were electrophoresed 
on SDS-PAGE gels using standard conditions. The proteins were transferred to 
nitrocellulose membranes, which were probed with the following antibodies: total 
HER2 (Cell signaling, 4290); phosphor HER2 (Tyr 1221/1222, Cell signaling, 
2243); total ERK (Cell signaling, 4695); phosphor ERK (Cell signaling, 9101); total 
Akt (Cell signaling, 4691); phosphorAkt (Cell Signaling, 4060); Caspase 3 
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(Oncogene); GAPDH (Santa Cruz, FL-335). The antibody dilutions for all detection of 
proteins were 1:1000.
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CHAPTER 3 Surface Glycan Localization and Purification 
 
3.1 Introduction 
3.1.1 Glycosylation 
Glycosylation is a critical post-translational modification (Fig. 3.1). Protein, 
lipids, tRNA and many secondary metabolites can be modified by glycosylation 
[68]. For example, glycosylation of proteins, which is important for protein folding, 
trafficking and stability [69], may govern biological homeostasis and affect organ 
development [70]. Glycoproteins comprise ~ 50% of the total cellular proteome 
and > 90% of the secreted proteome [71, 72]. Besides adding diversity to the protein 
structure, protein glycosylation may also modulate signal transduction and other 
functions. Glycosylation inside cells is mainly involved in intracellular signal 
pathways while protein glycosylation on the cell surface supports the 
communication and responds to extracellular stimuli [73, 74]. 
Alterations in the glycosylation include changes in the sites occupied by 
glycans and the glycan structures [75, 76]. Disruption of normal glycosylation is 
associated with hereditary and chronic disease such as cancer, diabetes, 
cardiovascular, inflammatory, neurological and neuromuscular diseases [75-77]. The 
glycoproteins in these diseases have been broadly studied for the purpose of 
diagnosis and treatment [76, 78]. However, to further investigate the function of 
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Figure 3.1. Different type of glycosylation. Figures download from the websites: 
http://www.piercenet.com/method/protein-glycosylation. 
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glycoproteins, protocols of imaging and enrichment of glycoproteins are still in demand. 
 
3.1.2 Glycoproteomics and Glycomics 
Glycoproteomics and glycomics refer to two approaches used for the 
characterization of specific targets’ (i.e. cell, tissue or organ) glycoproteome and 
glycome from an extracted protein mixture (Fig. 3.2) [75, 76, 79, 80]. For 
glycoproteomics, glycosylated proteins were enriched with certain techniques and 
then analyzed by LC/MS/MS (Liquid Chromatography/Mass Spectrometry/Mass 
Spectrometry) for protein species and glycosylation sites [80]. For glycomics 
analysis, the glycans are usually released from the glycomolecules and the 
composition and structure are analyzed either by mass spectrometry separately or 
with chromatographic techniques [80].   
Three different approaches were often applied to glycoproteomics: lectin 
affinity chromatography [81], antibody affinity chromatography [82] and metabolic 
labeling followed by specific interaction or reaction chromatography [83]. 
Depending on the methods chosen for enrichment and data analysis, the databases of 
glycoproteomics and glycomics might have variety among study groups. Thus, 
integration of all databases became more and more important. Certain programs 
have been established to merge databases for glycoproteomics [84, 85].  
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Figure 3.2. Schematic figure of protocol for glycoprotein purification using azide-alkyne cycloaddition reaction. Azide labeled non-
natural sugar will be incubated with cells. After reacted with alkyne conjugated reporter, glycoprotein will be enrichment by 
chromatography and applied to LC/MS/MS analysis. Figure was adapted from “Slade P.G. et al, 2012, J of proteome Res.” paper with 
copy right permission.  
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3.1.3 Click chemistry and its applications in bioorthogonal chemistry  
Click chemistry is very often used in the imaging and enrichment of 
glycoproteins. Click chemistry is first reported by Dr. Sharpless group in 2001 [86]. 
It refers to certain reactions that is modular, wide in scope, high yields, generate 
inoffensive byproducts and be stereospecific [86]. One of the most famous click 
reactions is the azide-alkyne cycloaddition using Cu(I) as the catalyst [87]. 
As showed in Fig. 3.3, using this reaction and analogue reactions, some 
companies have developed certain kits with alkyne or azide conjugated beads to 
enrich glycosylated proteins [79, 88]. Fluorescence probes with azide or alkyne 
groups were also synthesized to determine the localization of target molecules 
which could be labeled by corresponding alkyne or azide [89].  
Because copper might be toxic to live cells, Bertozzi and coworkers introduced 
two reactions that had better biocompatibility with intracellular environment and 
coined them as bioorthogonal reaction [90, 91]. Bioorthogonal reactions are 
chemical reactions that can occur inside of living systems without interfering with 
native biochemical processes [90]. One of the bioorthogonal reactions is called 
Staudinger ligation reaction, which allows azide react with triacrylphosphines (see 
Fig. 3.3) in live cells [92]. As first reported for bioconjugation usages in 2000 by 
Dr. Bertozzi’s group [90], this reaction has already been applied to imaging and 
protein enrichment in live cells and mice [91, 93]. The other reaction is termed 
Strain-promoted alkyne-azide cycloaddition (SPAAC) [94]. This reaction between 
azide and cyclooctynes has a faster reaction rate and do not need a copper catalyst 
(Fig. 3.3) [88, 94].   
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Figure 3.3. Bioorthogonal reactions for proteins labeling. Three reactions were shown 
here: Staudinger ligation, Cu-catalyzed Azide-Alkyne Cycloaddition and Strain Promoted 
Azide-Alkyne Cycloaddition reactions. Figure was adapted from book “Mass 
Spectrometry of Glycoproteins: Methods and Protocols, B. W. Zaro, et. al.” with copy 
right permission. 
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3.1.4 Bioorthogonal chemical reporters for glycoprotein labeling 
Bioorthogonal chemical reporters are non-natural molecules which could be 
incorporated into different biomolecules like glycan, protein and RNA in vivo 
without interrupting the molecular properties [86]. They may containing small tags 
i.e. azide and alkyne, which are small in size and metabolically stable [88, 95]. To 
study protein glycosylation, saccharides precursors tailored with such kind of tags 
were designed, synthesized and applied to label glycans [88]. Some typical reporters 
for the biorthogonal labeling of different saccharides are showed in Fig. 3.4. 
Basically, those bioorthogonal saccharides precursors (Fig. 3.4) may be 
incorporated to glycans through different endogenous salvage pathway [96, 97]. As 
a result, the azide/alkyne groups can be presented on the glycosylated proteins. By 
reacting with the affinity reporters (e.g. biotin motif or microbeads), glycoproteins 
could be enriched for downstream analyses like Western-blot, in-gel imaging and 
mass spectrometry [73, 88, 91, 96, 98]. Labeled glycoprotein can also be imaged in 
live cells or animals with fluorescent reporters [92]. For example, using a DIFO-
Alexa Fluor 488 conjugate, Bertozzi’s group has successfully imaged the 
glycosylation on the cell surface [98].  
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Figure 3.4. Structures of bioorthogonal chemical reporter for glycosylation. Figure was adapted from book “Mass 
Spectrometry of Glycoproteins: Methods and Protocols, B.W.Zaro, et. al.” with copy right permission. 
4
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3.1.5 Applications of bioorthogonal chemical reporters in glycosylation studies 
Bioorthogonal reporters have variety applications in the study of glycosylation. 
Among them, protocols of glycoproteins imaging and enrichment are well 
established [79, 88, 95, 98, 99].  
Different fluorescent probes have been used to image glycoproteins [88, 95, 
98]. For example, quantum dots, which were great fluorescent reporters with less 
photo bleach and increased brightness [100], have been applied to the imaging of 
glycosylation. As it could be modified in variety ways, this technique had not only 
been applied to the imaging of glycoprotein [101, 102] but also used to interrupt 
glycoprotein interactions [103, 104]. Another imaging technique using 
dibenzocyclooctyl conjugated fluorescent probes was also broadly studied. Although 
different techniques were applied to the imaging of glycosylation, no detailed 
reports were published to compare the effect of those staining protocols. Depending 
on the properties of fluorescent probes, different information of glycosylation may 
be provided by those protocols. To image glycoproteins in cell compartments, two 
fluorescent probes including dibenzocyclooctyl-fluorescein and dibenzocyclooctyl-
quantum dots were applied to breast cancer cell lines in this chapter. Both the total 
glycosylation and the membrane specific glycosylation were tracked using these two 
probes. The experiments provided versatile information on the localization of 
glycoproteins in breast cell models. 
Recently, purification of bioorthogonal reporter labeled glycoprotein has 
become commercially available [79, 83, 99]. However, the nonspecific binding of 
proteins is always a challenge in those assays. To develop a better enrichment 
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protocol for glycoprotein, our lab synthesized Si-alkyne beads with a disulfide bonds, 
which could be used to release glycoproteins after enrichment. This may minimize the 
background from non-specific binding as well as increase the recovery of glycoproteins 
by this specific releasing procedure using disulfide [99]. 
 
3.2 Results and Discussion  
3.2.1 Structures of fluorescent probes 
Two different fluorescent probes were used in our study. One was DBCO-
fluorescein by conjugating fluorescein to dibenzocyclooctyl (Fig. 3.5.a). The other is 
called DBCO-QT which used CdSe/CdZnS quantum dots as fluorescence cores and 
coated by polymers (PEG: Imidazole: Amine = 4:4:2) functionalized with 
dibenzocyclooctyl (Fig. 3.5.b). This DBCO-QT was designed and synthesized by our lab 
in collaboration with Dr. Andrew Greytak’s lab (Department of Chemistry and 
Biochemistry, University of South Carolina). The properties of fluorescent cores 
determined the localization and the detection limits of the fluorescent probes. DBCO-
fluorescein, as a small organic fluorescent probe, can diffuse into cells and react with 
targets all over the cells. Thus, it may image the total glycoproteins. As the diameter of 
quantum dots is around 3 nm, it can hardly diffuse into cells, which lead to the reaction 
sites limiting to the cell surface. Also the strong fluorescence from quantum dots helped 
to bring up the weak signal from cell membrane. The schematic labeling process is 
showed in Fig. 3.6.   
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Figure 3.5. Structures of fluorescent probes for labeled glycoproteins. Structures of a) 
DBCO-FL (Dibenzocyclooctyl-fluorescein) and b) DBCO-QT (Dibenzocyclooctyl-
quantum dots). 
  
CdSe 
CdZnS 
DBCO-QT  DBCO-FL  
a) b) 
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Figure 3.6. The schematic illustration of metabolic labeling and detection of 
glycoproteins with fluorescent probes. Cells were first fed with bioorthogonal chemical 
reporter Ac4ManNAz or Ac4GalNAz for certain time. Fluorescent probes were then 
incubated with cells for 0.5 hour in dark. Images were taken right after the staining. 
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3.2.2 Staining results of DBCO-fluorescein 
N-azidoacetylmannosamine-tetraacylated (Ac4ManNAz) and N-
azidoacetylgalactosamine-tetraacylated (Ac4GalNAz) could be processed by the N-
acetyl-D-mannosamine (ManNAc) and N-acetylgalactosamine (GalNAc) salvage 
pathways and incorporated into glycosylated proteins [96, 105, 106]. Ac4ManNAz 
labeled those glycoproteins with sialylated glycans [106]. Ac4GalNAz was mostly 
incorporated as GalNAz for O-glycosylation [96]. Since sialylated glycans were 
always at the end while GalNAc was the first saccharide in O-glycosylation [107], 
Ac4ManNaz might be incorporated to the end of glycans and Ac4GalNAz might be 
the first one. 
Glycosylation of proteins was different for cancer and normal cells. Not only 
more sialic acids were incorporated into glycans, but also sialylated glycoproteins 
were very often overexpressed in cancer cells [108-110]. With the Ac4ManNAz and 
Ac4GalNAz synthesized by Dr. Li Cai (Division of Mathematics and Science, 
University of South Carolina, Salkehatchie), we successfully labeled and imaged 
glycoproteins in MDA-MB-231 cell lines [111]. Because breast cancer cells might 
have higher level of sialylated proteins compared to normal cells, a higher level of 
cell membrane localized fluorescence was expected in cancer cells labeled with 
Ac4ManNAz. To prove this, another two breast cell lines, MCF10A and MCF7 
were chosen. These three cell lines could be used to represent for different stages of 
breast cancer, normal state (MCF10A), proliferation state but not metastasis (MCF7) 
and metastasis state (MDA-MB-231). As cancer cell lines, MCF7 and MDA-MB-
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231 should have higher level of fluorescent signals on the cell membrane for ManNAz 
labeled cells.  
To detect the total glycosylation, the cell lines were labeled with 100 µM 
Ac4ManNAz for different time (1 day, 2 days, 3 days). The bioorthogonal reporter 
labeled glycosylation was imaged by reacting with DBCO-fluorescein (Fig. 3.7). Results 
showed that labeling time did affect the fluorescence intensity. The cells from Day 1 had 
higher fluorescence signal than those from day 2 and day 3, which might be due to the 
degradation of Ac4ManNAz. The fluorescent signals were spread all over the whole cells 
without preference on any individual organelle. To compare the staining intensity of 
different cell lines, three cell lines were labeled and stained parallel. Fig. 3.8 showed 
MCF7 and MDA-MB-231 had higher fluorescence intensity than MCF10A. This result 
further confirmed the previous findings on the overexpression of sialic acid in cancer 
cells [108-110]. 
 
3.2.3 Staining results of Quantum dots-DBCO 
Quantum dots as nanometer sized particles were a new class of fluorescent probes 
for biomolecular and cellular imaging [101, 102]. Quantum dots have been considered as 
ideal imaging probes due to many unique properties including the size-tunable light 
emission, improved signal, simultaneous excitation of multiple colors and resistant 
against photo bleaching [100]. Yi Shen from Dr. Andrew Greytak’s lab (Department of 
Chemistry and Biochemistry, Columbia, University of South Carolina) synthesized the 
polymer coating CdSe/CdZnS quantum dots conjugated with DBCO based on their 
recently published protocols.   
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Figure 3.7. Staining of glycoprotein using DBCO-FL. MCF10A, MCF7 and MDA-MB-
231 cells were incubated with 100 µM Ac4ManNAz for 1, 2 and 3 days. The cells were 
then fixed and reacted with DBCO-FL. Labeling time lead to different intensity of 
fluorescence staining. The 1 day time point was used for later experiment for the 
incubation time of bioorthogonal chemical reporters. Scale bar: 100 µm. 
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Figure 3.8. Staining of glycoprotein using DBCO-FL. MCF10A, MCF7 and MDA-MB-
231 cells were incubated with 100 µM AC4ManNAz for 1 d. The cells were then fixed 
and reacted with DBCO-FL for 0.5 h at room temperature. The experiment was 
performed at the same time for all three cell lines. Identical exposure time was applied to 
compare the intensity of fluorescence among cell lines. Scale bar: 50 µm. 
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The diameter of quantum dots was around 3 nm, which made the quantum 
dots hard to diffuse into cells, resulting in a preferred interaction with cell surface 
glycoproteins. As shown in Fig. 3.9, using DBCO-QT, sialylated glycoproteins 
labeled by AC4ManNAz on the cell surface could be probed for three breast cell 
lines. While no significant fluorescent signal was found for MCF10A, both MCF7 
and MDA-MB-231 shown intense fluorescence signals on the cell membrane. 
Therefore, the imaging method using quantum dots provided a potential way to 
detect and quantify the level of cell surface glycosylation.  
 
3.2.4 Structure and stability of Si-Alkyne probe for glycoprotein enrichment 
Besides the localization of glycoproteins, the compositions and structures of 
glycoproteome are also important for the studies of glycosylation in cancer. Current 
methods for glyco-molecules enrichment may have strong background from non-
specific binding to beads. To minimize the non-specific binding and increase the 
recovery rate, our lab synthesized a Si-bead conjugated with a disulfide bond and a 
triple bond (Fig. 3.10). The stability of this probe could be identified by the 
fingerprint peaks of two carbonyl groups using infrared spectroscopy (Shimadzu 
FTIR Spectrophotometer). Since the click-reaction needed longer incubation, we 
first evaluated the stability of beads in click-reaction buffer 7 (Table 3.1). The 
results in Fig. 3.11 showed the beads (and their coatings) were in this buffer for as 
long as 3 days. 
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Figure 3.9. Staining of glycoprotein using DBCO-QT. MCF10A, MCF7 and MDA-MB-
231 cells were incubated with 100 µM AC4ManNAz for 1 d. The cells were then fixed 
and reacted with DBCO-QT for 0.5 h at room temperature. The experiment was 
performed at the same time for all three cell lines. Identical exposure time was adopted to 
compare the intensity of fluorescence among cell lines. DAPI (4’,6-diamidino-2-
phenylindole) staining was also performed to show the localization of nucleus. Scale bar: 
10 µm. 
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Figure 3.10. Schematic pictures to show the synthesis and characterization of Si-beads. a) 
The organic pathway to modify the Si-beads. b) The IR spectrum used to characterize the 
modification of the beads. 
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Figure 3.11. Stability of S-S bonds in buffer 7. Beads were incubated with buffer 7 for 1 
to 3 d. After washed with 100 mM Tris-HCl pH 8 buffers, beads were dried and the IR 
was read. The disulfide bond could be stable in buffer for up to 3 d. 
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Table 3.1. Buffers used in enrichment of glycoprotein with Si-beads 
Buffer  Property Composition 
Buffer 1 Urea lysis buffer 
8 M urea, 200 mM Tris-HCl pH 8.0, 4% CHAPS, 
1 M NaCl, 2 × protease inhibitor 
Buffer 2 NP40 lysis buffer 
50 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM 
EDTA, 1% NP-40 
Buffer 4 Wash buffer 
2% SDS, 1% NP-40, 150 mM NaCl, 1% 
NaDeoxycholate, 50 mM Tris-HCl pH 7.5 
Buffer 5 Click reaction stock 
2 mM L-Histidine, 2 mM CuSO4, 20 mM 
Sodium Ascobic Acid, 83.5 mM Tris-HCl pH 8.0 
Buffer 7 Click reaction buffer 1:1 mixture of buffer 4 and buffer 5. 
Buffer 9 Wash buffer 
100 mM Tris-HCl pH 8.0, 1% SDS, 250 mM 
NaCl, 5 mM EDTA 
Buffer 10 Wash buffer 8 M urea and 100 mM Tris-HCl pH 8.0 
Buffer 11 Wash buffer 20% acetonitrile 
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3.2.5 Efficiency of glycoprotein enrichment 
The enrichment of glycoproteins was involved in the conjugation reaction between 
bioorthogonal labeled protein and specific modified beads. The cell lysates with 
Ac4GalNAz labeled glycoproteins were incubated with the beads in click reaction buffer. 
Azide tag on the glycoproteins was reacted with the alkyne on the beads and formed a 
1,2,3-triazole ring. After conjugated to the beads, the glycoproteins could undergo 
stringent wash steps and finally be released from the beads either by reducing agents to 
break the disulfide bond or trypsin digestion. To control for the efficiency of each steps 
for glycoproteins enrichment, a fluorescent dye DCP4, which mimic proteins labeled by 
Ac4GalNAz, was incubated with the beads. DCP4 had an azide group that could be 
reacted with the triple bonds through cupper (I) catalyzed-azide alkyne cycloaddition 
reaction. Enrichment products could be tracked by the fluorescence of DCP4 using plate 
reading.  
Samples from each step were collected and the fluorescent intensity was read on 
SpectraMax M2 with excitation at 560 nm and emission at 600 nm. As we expected, 
fluorescent signals in washing buffers decreased from 18698 to 2000 after 20 times 
washing (Fig. 3.12) for Si-Alkyne beads. It was similar for Si-COOH control beads, of 
which the fluorescent signal dropped faster (from 12854 to 39.8 after 7 washes). This 
decrease in fluorescence was due to a reduction in the non-specific binding of dyes to the 
beads. Fluorescent intensity was comparable for the three times of elution with 50 mM 
DTT for Si-Alkyne (6150, 4374, 4514). This low efficiency in elution might be due to the 
hydrophobicity of DCP4. After reacting with the triple bond, DCP4 might wrap around 
the disulfide bond and kept it from interacting with DTT. 
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Figure 3.12. Purification control for the enrichment of glycoproteins. a) Structure of the DCP4 fluorescent probe. b) The 
fluorescent intensity of solution at each steps of process. Stringent wash could help to minimize non-specific binding of dyes. 
Elution with protein loading buffer and 50 mM DTT could release DCP4 dyes from the beads. 
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3.2.6 Glycoproteins enrichment with Si-Alkyne beads 
To optimize the enrichment protocols, two different lysis buffers and two different 
releasing methods for glycoproteins enrichment were tested by the same protocol 
mentioned above. Cells were labeled for 1 day using 100 µM GalNAz prior to collection. 
Both Urea Buffer (Fig. 3.13) and NP-40 buffer (Fig. 3.14) could lyse 90% of cells. After 
enrichment and recovery of glycoproteins, no specific protein bands were visualized from 
DTT elution. To double check the elution efficiency, trypsin digestion was applied to 
collect proteins on the beads. However, trypsin did not help to improve the results (Fig. 
3.15). One explanation was that the labeled proteins might not react with the beads 
efficiently. We might need to modify and improve the properties of the beads to allow 
higher efficiency in click reaction between beads and proteins. 
 
3.3 Conclusion 
To compare the glycosylation level among three breast cell lines, the biorthogonal 
chemical reporters, i.e. AC4ManNAz and AC4GalNAz, were used to labeled cells and 
two different detection probes were applied to track glycoproteins. DBCO-fluorescein 
could diffuse into cells while DBCO-QT predominantly recognizes azide tags on the cell 
membrane. Total glycosylation level among cells could be analyzed by DBCO-
fluorescein while the cell membrane localized glycoproteins could be detected by DBCO-
quantum dots. Both total glycosylation and cell surface glycosylation level were higher in 
the two breast cancer cell lines MCF7 and MDA-MB-231 compared to normal control 
cell lines. 
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Figure 3.13. Enrichment of glycosylated protein using Si-Alkyne beads: choice of lysis 
buffer. Urea lysis buffer was used to lysis HEK293T cells labeled with 100 µM GalNAz 
for 1 d. Proteins were harvest and incubated with beads for 1 d in click reaction buffer. 
Proteins were eluted in loading buffer plus 200 mM DTT. No significant enrichment 
protein bands were seen for labeled cells compared to unlabeled cells. 
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Figure 3.14. Enrichment of glycosylated protein using Si beads-choice of lysis buffer. 
NP-40 lysis buffer was used to lysis HEK293T cells labeled with 100 µM GalNAz for 1 
d.  Proteins were harvest and incubated with beads for 1 d in click reaction buffer. 
Proteins were eluted in loading buffer plus 200 mM DTT. No significant enrichment 
protein bands were seen for labeled cells compared to unlabeled cells. 
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Figure 3.15. Enrichment of glycoprotein using Si beads-choice of protein releasing 
methods. Urea buffer and NP-40 lysis buffer were used to lysis HEK293T cells labeled 
with 100 µM GalNAz for 1 d. Proteins were harvest and incubate with beads for 1 d in 
click reaction buffer. Proteins were digested on beads by trypsin. No significant 
enrichment protein bands were seen for labeled cells compared to unlabeled cells. 
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Since Si is an inorganic reagent, the nonspecific bindings between biomolecules and 
the beads could be reduced. This may help to improve the efficiency of protein 
enrichment. To achieve this research purpose, our lab synthesized the si-probes with 
disulfide bond and triple bond. The disulfide bond could be used to release the proteins 
from the beads after enrichment procedures. This design could obtain the intact proteins 
as well as intact glycans instead of peptides fragments (from trypsin treatment). The 
stability of this bead was tested in a combination of washing buffer and click reaction 
buffer. The disulfide bonds were still stable after 3 days incubation. To further confirm 
the efficiency of each purification step, a control experiment using a fluorescent probe to 
mimic labeled glycosylated proteins was performed. The fluorescent signals from control 
experiment confirmed the click reaction was successfully reacted. The DCP dyes 
conjugated to the beads could then be release by DTT treatment to break the disulfide 
bond. Although we confirmed the recovery of the controlled fluorescence dyes, we did 
not succeed in developing enrichment protocols for glycoprotein. This might be attributed 
to the low accessibility of proteins to the triple bounds, i.e. the linker was not long 
enough to give high reaction efficiency between triple bond and azide group on labeled 
proteins. We could try beads with longer linker later for this project. We might also coat 
the beads with polymers to help the protrusion of the triple bond end. 
 
3.4 Experimental Section 
3.4.1 Cell Maintenance 
The MCF10A and MDA-MB-231 cell lines were kindly gifts from Prof. Hexin Chen 
(University of South Carolina, Department of Biology Science). MCF7 cell line was 
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purchased from American Type Culture Collection (Cat. No: HTB-22). MCF10A 
were maintained in DMEM:F12 (1:1) medium with 5% horse serum, 10 µg/mL 
insulin, 20 ng/mL EGF, 100 ng/mL cholera toxin, 0.5 µg/mL hydrocortisone. MCF7 
cells were maintained in DMEM-high glucose medium with 10 µg/mL Insulin and 
10% FBS. MDA-MB-231 was cultured in DMEM-high glucose medium with 10% 
FBS. Please see Chapter 1 for HEK293T cell line information. All cells were in a 
water-saturated atmosphere of 5% CO2 and 95% air at 37°C. 
 
3.4.2 Staining of cells with DBCO-FL and DBCO-QT 
Cells were seeded at 1 × 105 cells/well in the 12-well plates and allowed to 
grow overnight. The Ac4ManNAz and Ac4GalNAz were added to the cells the next 
day and incubated for indicated time. On the day of imaging, cells were washed 
three times with PBS and fixed by 4% paraformaldehyde for 15 min at room 
temperature. After being washed three times with PBS, the samples were blocked in 
100 mM glysine for 30 minutes. DBCO-FL (10 µM final concentration) or DBCO-
QT (20 nM final concentration) were incubated with cells for 30 minutes. Cells were 
washed three times and kept in PBS in dark before imaging. DAPI were added to the 
PBS at 5 μg/mL final concentration without washing. Confocal images were taken 
by Olympus X81 fluorescence microscopy. 
 
3.4.3 Stability of Si-beads 
Si beads were incubated in the buffer 7 for indicated time. After washed with 
PBS for three times, the beads were air-dry overnight. The infrared spectra were 
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recorded with a Shimadzu FTIR Spectrophotometer. Buffer compositions were showed in 
Table 3.1. 
 
3.4.4 Beads preparation and reactivity with DCP4 
One day before protein collection, beads were blocked with 0.0001% poly vinyl 
alcohol in 100 mM Tris-HCl pH 8.0 overnight at 4 ºC. After washed three times with 100 
mM Tris-HCl pH 8.0, 15 mM (around 15 mg) beads was incubated with 5 mM DCP-4 for 
18 hours in Buffer 7. The beads were then pellet and washed five times with Buffer 9, ten 
times with Buffer 10 and five times with Buffer 11. Then the dyes that conjugated to the 
beads were eluted by boiling the beads with protein loading buffer (BioRad, Cat. No: 
161-0737) plus 50 mM DTT for 5 min. The washing buffer and elution solution were 
collected and pipetted into 96 well to read the fluorescence (excitation at 560 nm and 
emission at 600 nm). 
 
3.4.5 Protein purification and SDS-PAGE verification 
HEK293T cells were seeded at 3 × 106 /plate in 10 cm plate. Each sample needs 8 
plates in order to collect 5 × 107 cells. Cells were dissociated by 0.5 mM EDTA in PBS 
for 10 minutes. Harvested cells were subjected to lysis buffer (Urea buffer or NP40 
buffer) and homogenized using Pro Scientific hand-held homogenizer (PRO-01-02200 
PRO200). The total cell lysates from NP40 buffer were further cleared by methanol 
chloroform precipitation and resolved in lysis buffer II. Protein concentrations were 
measured using Thermo Commasie Plus Protein reagents.  Equal amount of proteins were 
subject to beads pre-blocked with PVA (polyvinylalcohol) and incubated with Buffer 5 
for 18 hours. The beads were then pellet and washed five times with Buffer 9, ten times 
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with Buffer 10 and five times with Buffer 11. Then the glycosylated proteins that 
conjugated to the beads were eluted by boiling the beads with protein loading buffer 
200 mM DTT for 5 minutes and briefly centrifuged. For trypsin digestion, 0.005 
µg/µL trypsin (final concentration) was incubated with beads in the digestion buffer 
(100 mM Tris, 2 mM CaCl2, 10% acetonitrile) for 8 hours at 37ºC. The digestion 
solutions were collected by briefly pellet the beads. Cell lysates and eluting 
solutions were prepared. Equal amounts of protein were electrophoresed on SDS-
PAGE (4%-10%). The gels were stained with Lagsafe Gel Blue (Cat. No 786-35) 
and images were taken by Bio-Rad Gel imaging system (GelDoc XR).  
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CHAPTER 4 Assessment of Aldehyde Dehydrogenase 2 (ALDH2) in Live Cells 
 
4.1 Introduction 
4.1.1 ALDH family proteins 
Aldehydes are highly reactive electrophilic compounds that play a vital role in 
physiological process such as mutagenic, carcinogenic and cytotoxic detriment [112, 
113]. Various reactive aldehydes can be produced from different endogenous precursors 
[114]. Aldehydes can be further oxidized to acetic acid and detoxified by aldehyde 
dehydrogenase (ALDH) [112] (Table 4.1). The ALDH family currently has 19 members 
(Table 4.1) [115]. Due to their important functions in aldehyde metabolism, mutations 
and polymorphisms of ALDH genes (loss of function) are often found to be associated 
with different diseases in humans and rodents [113]. In particular, polymorphisms of 
ALDH2 (a subtype of ALDH) that resulted in loss of function of ALDH2, were 
associated with an increased risk for various cancers, including oropharyngolaryngeal, 
esophageal, stomach, colon, lung, head and neck cancers [116, 117].  
 
4.1.2 Cancer stem cell model 
Cancers are heterogeneous, multicellular entities that arise when an epigenetic or 
genetic change occurs in normal cells, which disrupt normal cellular homeostasis [118, 
119]. Currently there are two models of heterogeneity for solid cancer cells [120] (Fig. 
4.1). One model believes cancer cells include many different subtypes 
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Table 4.1. Human ALDH family proteins [121] 
ALDH 
isoenzyme 
Cellular 
Localization 
Tissue/Organ Distribution Disease 
Associated with 
Polymorphisms 
ALDH1A1 Cytosol Liver, kidney, red blood cells (RBCs), 
skeletal muscle, lung, breast, lens, 
stomach mucosa, brain, pancreas, 
testis, prostate, ovary 
Perhaps 
alcoholism 
ALDH1A2 Cytosol Testis, small amounts in liver, kidney Spina bifida 
ALDH1A3 Cytosol Kidney, skeletal muscle, lung, breast, 
testis, stomach mucosa, salivary 
glands 
 
ALDH1B1 Mitochondria Liver, kidney, heart, skeletal muscle, 
brain, prostate, lung, testis, placenta 
Various 
phenotypes 
ALDH1L1 Cytosol Liver, skeletal muscle, kidney  
ALDH1L2 Unknown   
ALDH2 Mitochondria Liver, kidney, heart, skeletal muscle, 
lens, brain, pancreas, prostate, spleen 
Ethanol-induced 
cancers, 
hypertension 
ALDH3A1 Cytosol, 
nucleus 
Stomach mucosa, cornea, breast, lung, 
lens, esophagus, salivary glands, skin 
Various 
phenotypes 
ALDH3A2 Microsomes, 
peroxisomes 
Liver, kidney, heart, skeletal muscle, 
lung, brain, pancreas, placenta, most 
tissues 
Sjögren-Larsson 
syndrome 
ALDH3B1 Cytosol Kidney, lung, pancreas, placenta  
ALDH3B2 Unknown Parotid gland  
ALDH4A1 Mitochondria Liver, kidney, heart, skeletal muscle, 
brain, placenta, lung, pancreas, spleen 
Type II 
hyperprolinemia 
ALDH5A1 Mitochondria Liver, kidney, heart, skeletal muscle, 
brain 
Г-
hydroxybutyric 
aciduria 
ALDH6A1 Mitochondria Liver, kidney, heart, skeletal muscle Developmental 
delay 
ALDH7A1 Cytosol, 
nucleus, 
mitochondira 
Fetal liver, kidney, heart, lung, brain, 
ovary, eye, cochlea, spleen, adult, 
spinal cord 
Pyridoxine-
dependent 
epilepsy 
ALDH8A1 Cytosol Liver, kidney, brain, breast, testis  
ALDH9A1 Cytosol Liver, kidney, heart, skeletal muscle, 
brain, pancreas, adrenal gland, spinal 
cord 
Various 
phenotypes 
ALDH16A1 Unknown Neuronal cells  
ALDH18A1 Mitochondria Kidney, heart, skeletal muscle, 
pancreas, testis, prostate, spleen, 
ovary, thymus 
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which have the potential to proliferate extensively, but none can form spheres or colonies 
in clonogenic assays [120]. Cancer stem cell model believes that a subset of cancer cells 
called cancer stem cells (CSCs) can consistently proliferate extensively in clonogenic 
assays and form new tumors on metastasis sites [120, 122, 123]. 
Cancer stem cells were first isolated by Dr. John Dick in leukemia in 1994 using 
CD34+CD38- as the cancer stem cell marker [124]. The first report of cancer stem cells in 
solid tumors came in 2003 using a CD44+CD24- marker for breast cancer [125]. CSCs 
have also been identified in several other cancer types, including solid tumors of the liver, 
pancreas, brain, colon and prostate [118, 124-134]. 
 
4.1.3 ALDH proteins may be used as cancer stem cell marker 
In 1990s, Jones and Storms [135, 136] developed a technique known today as the 
Aldefluor Assay to stain and isolate live hematopoietic stem cells with high ALDH 
activity (Fig. 4.2). Cells with high ALDH activity uptake the fluorescent substrate 
BODIPY-aminoacetaldehyde (BAAA) by passive diffusion and then convert BAAA into 
negatively-charged BODIPY-aminoacetate (BAA-). BAA- then retains inside cells, 
which makes the subset of cells with a high ALDH activity (ALDH-hi) become highly 
fluorescent. These ALDH-hi populations can be distinguished through comparison to the 
diethylaminobenzaldehyde (DEAB) negative control (a specific inhibitor of ALDH 
[137]) (Fig. 4.2.b). To date this method has been applied to different cell types to identify 
stem cells or cancer stem cells [138-142]. 
As the BAAA is distributed all over the cell, this assay basically measures the 
activity of all ALDHs expressed in cells. It is non-specific and may be affected by cell  
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Figure 4.1. Cancer stem cell models. a) Cancer cells of many different phenotypes have 
the potential to proliferate extensively, but any one cell would have a low probability of 
exhibiting this potential in an assay of tumorigenicity. b) Most cancer cells have only 
limited proliferative potential, but a subset of cancer cells (cancer stem cell) consistently 
proliferate extensively in clonogenic assays and can form new tumors on transplantation. 
Figure was adapted from “Reya, T., et al., Nature, 2001” paper with copy right 
permission. 
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Figure 4.2. Aldefluor Assay. a) ALDH converts BODIPY-aminoacetaldehyde (BAAA) to 
BODIPY-aminoacetate (BAA-). b) Schematic mechanism of Aldefluor Assay. Cells 
expressing ALDH uptake BAAA and convert it to BAA-. BAA- is then retained inside 
cells, causing the subset of ALDH-Hi cells to become highly fluorescent. Cold assay 
buffer is added to prevent the ATP-binding cassette (ABC) transporters to pump the 
BAA- out of the cells. As a negative control, diethylaminobenzaldehyde (DEAB), which 
is a specific ALDH inhibitor, is used to quench the activity of ALDH-Hi cells and 
prevent the cells to become fluorescent. Figure was adapted from “Storms, R.W., et al, 
Proc Natl Acad Sci, 1999” and “Ma, I., et al., Stem Cell Rev and Rep, 2011” with copy 
right permission. 
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types. It will be interesting to know the correlations between specific members of ALDHs 
and cancer stemness. 
 
4.1.4 ALDH2 proteins might be a marker for cancer stem cells 
ALDH2 encodes a 50 kDa mitochondrial matrix protein that is constitutively 
expressed in a variety of tissues including liver, kidney, heart, lung and brain [143]. 
ALDH2 is the primary enzyme involved in the oxidation of acetaldehyde (Km < 0.1 
µM) during ethanol metabolism [144]. Polymorphisms of ALDH2 that leads to loss 
of function of ALDH2 was associated with an increased risk for various cancers, 
including oropharyngolaryngeal, esophageal, stomach, colon, lung, head and neck 
cancers [116, 117].  Alcoholic individuals carrying ALDH2 (ALDH2*2, E487K) 
mutations displayed increased levels of acetaldehyde-derived DNA adducts, which 
indicated a potential role of ALDH2 mutation in DNA damage and cancer 
development [144]. ALDH2*2 was also associated with a lack of nitroglycerin 
efficacy in Chinese patients [145], the myocardial infarction in Korean patients and 
the hypertension in Japanese patients [146, 147]. In addition, ALDH2 played a 
major role in the scavenging of the neurotoxic aldehyde metabolite of dopamine, 
DOPAL (Km= 4.2 µM) [113, 148], which might explain why  ALDH2*2 was 
associated with an elevated risk for late on-set Alzheimer in Japanese [149] and 
Chinese [150]. 
Because of its important enzyme activity, ALDH2 might play an important role 
in cancer stem cell signaling and might be identified as a marker for cancer stem 
cells.  
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4.1.5 Methods to study ALDH2 protein 
Some traditional methods i.e. in vitro activity assay, immunohistochemistry and 
Western-blot have been used to study ALDH2’s activity and expression in cancer [113, 
117, 134, 144, 148, 151]. Unfortunately, those methods have some disadvantages. First, 
these methods require the endogenous ALDH2 to be released from the cells, which kills 
the cells [152, 153]. For cancer stem cells, identifying and isolating the live cells are 
required to study their function and phenotype, especially their resistance to anti-cancer 
drug [120]. It will be more useful to study the ALDH2 enzyme activity in viable cells. 
Second, cross reactivity of antibodies against different ALDHs introduced non-specific 
binding [154, 155]. New methods needed to be developed to identify and isolate ALDH2-
high cells efficiently for further research purposes.  
To investigate the possibility of ALDH2 as a cancer stem cell marker, methods 
detecting ALDH2 activity in live cell were needed to be developed and optimized. For 
this purpose, our lab synthesized two different fluorescent probes: RSAAA and 
RSACOOH (Fig. 4.3). Using these two probes, we developed and optimized a new 
method to isolate cells with higher ALDH2 enzyme activity.  
 
4.2 Results and Discussion 
4.2.1 Structures and spectra of RSAAA and RSACOOH 
The structures of two fluorescence probes were present in Fig. 4.3. The schematic 
conversion route of these molecules was also showed. RSAAA can be in situ converted to 
RSACHO inside cells by a quick dehydration reaction. RSACHO could then work as a 
substrate for ALDH family proteins and be oxidized to RSACOOH in the presence of   
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Figure 4.3. Structures of RSAAA and RSACOOH probes and their possible conversion 
pathways in cells. The acetal structure of RSAAA can be easily transformed into 
RSACHO in situ. RSACHO then worked as substrate for ALDH2 and was oxidized to 
RSACOOH. 
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ALDH family proteins. As RSAAA had a positive charge, we postulated that it primarily 
localized in the mitochondria. Conversely, the negative charge on RSACOOH would 
make it easy to be pumped out of the cell. Thus, the cells with higher ALDH2 activity 
should have a lower fluorescence. 
ALDH2 is the predominant member of ALDH proteins in mitochondria [143, 144] 
and the major member to oxidize RSACHO. Therefore we hypothesized that the higher 
the activity of ALDH2, the lower the fluorescence signals (Fig. 4.4). As RSACHO was 
more reactive than RSAAA and might induce high background, RSAAA might be a 
better candidate to assay for ALDH2 activity.  
To test the fluorescence activity of RSAAA and the end product RSACOOH, their 
spectrum was measured on Varian Cary Eclipse Fluorescence Spectrophotometer (Fig. 
4.5). RSAAA had much higher fluorescence than the RSACOOH (Fig. 4.5.a). Their 
emission both peaked around 592 nm and their fluorescence could be tracked at the same 
excitation and emission range. To confirm the retention of RSAAA and RSACOOH in 
the cells, they were used to stained cells for 0.5 hour before the probes were removed and 
the cells were allowed to chase for different time. Fluorescence of cells was recorded in 
96 well plates with a SpectraMax M2 Microplate Reader (excitation: 536 nm; emission: 
592 nm). As shown in Fig.4.5.b, the fluorescence of RSACOOH staining cells dropped 
by 95% in the first 20 min after removing the fluorescence probe, while RSAAA staining 
cells retained 40% of fluorescence activity and eventually dropped to 20% after chasing 
for 115 min. These results confirmed the hypothesis on the intracellular retention of these 
two dyes. 
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Figure 4.4. Schematic mechanism of assay for ALDH2 activity. Cells expressing high 
ALDH2 uptook RSAAA and converted it to RSACOOH. RSACOOH was then pumped 
out of cells, which made the subset of ALDH2-Hi cells to become lower fluorescent. 
Cold assay buffer was added to prevent the ATP-binding cassette (ABC) transporters to 
pump out the RSAAA. As a negative control, diethylaminobenzaldehyde (DEAB), a 
specific ALDH1 and ALDH2 inhibitor, was used to quench the activity of ALDH2-Hi 
cells, which increased the cells fluorescent signal. 
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Figure 4.5. Fluorescent property and cell retention of RSAAA and RSACOOH. a) Fluorescence emission file of RSAAA and 
RSACOOH excited at 536 nm. RSAAA had higher fluorescence intensity than RSACOOH. They both give peak emission at 592 nm. 
b) Fluorescence Chase experiment of two dyes inside HCT15 cells. Cells were stained with two dyes for 0.5 h. The dyes were then 
removed and the fluorescence of cells was recorded at different time point. It was found that RSACOOH didn’t retain inside cells 
while more than 30% RSAAA still retain in the cells after 2 h.  
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4.2.2 ALDH2 expression and activity in model cell lines 
In order to develop the enzyme activity assay in live cell, cell lines with higher 
expression and activity of ALDH2 were needed. Colon cancers were known to have 
a various ALDH2 expression [156]. After searching for mRNA database of colon 
cancer cell lines, we found that the HCT115 might enrich in ALDH2 expression 
compared to HCT116 and SW620. To check the expression and activity of ALDH2 
in these cell lines, Quantitative Reverse Transcription Polymerase Chain Reaction 
(QRT-PCR) and in vitro activity assay were performed. Results from QRT-PCR 
showed ALDH2 expression in HCT15 cell line was approximately 12 times higher 
than that in SW620 (Fig. 4.6). ALDH2 activity assay confirmed that there were two 
fold differences between two cell lines (Fig. 4.7). Therefore, HCT15 was chosen for 
the following experiment.  
 
4.2.3 Substrate specificity of ALDH2 
To test whether RSAAA and RSACOOH might be the potential substrates for 
ALDH2, the in vitro ALDH2 activity assay was then performed using HCT15 cell 
lysates with these two probes. As showed in Fig. 4.8, RSAAA could be oxidized by 
cell lysate at a reaction rate around 700 µmol/min/g. The ALDH2 preferred 
substrate: propionaldehyde was around 2300 µmol/min/g. RSACOOH had a 
negative reading of reaction rate, which meant it could not be the substrate of 
ALDH2. The negative reading may be due to the interference from environment. 
Further control experiments should be performed validate the results. 
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Figure 4.6. Expression of ALDH2 in colon cancer cells. RT-PCR (a) and QRT-PCR (b) 
were performed on three colon cell lines HCT116, HCT15 and SW620. ALDH2 
expression was analyzed using the 2 –ΔΔCT method [157] for relative quantification. Star 
indicates significant difference in ALDH2 expression between HCT15 and the other two 
cell lines by student t test with a 95 confidence interval.HCT15 cells had the highest 
ALDH2 level. 
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Figure 4.7. Enzyme activity of ALDH2 in different cell lines. Enzyme activity assay of ALDH2 were performed using the cell lysates 
from HCT15 and SW620. a) The accumulation of substrate over time. b) The ALDH2 activity of two cell line. Star indicated 
significant difference in ALDH2 activity between HCT15 and SW620 by student t test with a 95 confidence interval. The HCT15 had 
higher ALDH2 activity than SW620.  
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Figure 4.8. Organic probes as ALDH2 substrates. RSAAA, RSACOOH and 
propionaldehyde were mixed with cell lysates and the ALDH2 reaction velocity were 
recorded for three substrates. Experiment was only performed once and need to be 
repeated to further validate the results.   
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4.2.4 Choice of inhibitor of ALDH2 
As showed in Fig. 4.4, to isolate ALDH2 high populations, an inhibitor for 
ALDH2 was also needed in the design of this protocol. A parallel control 
experiment with this specific inhibitor would be performed to set up a gate, which 
controlled the population of inhibitor group to around 1% of total population. This 
gate would be used to isolate ALDH2 high group in non-inhibitor group, which 
could be around 10% of the total population according to Aldefluo Assay. Three 
ALDH2 inhibitors reported in previous studies [137, 158, 159] were screened using 
in vitro activity assay (Fig. 4.9). The working concentrations of inhibitors were 
chosen according to the reference [137, 158, 159]. It was found that 15 µM DEAB 
could inhibit the activity as low as 35.4% of the control. Cyanamide could also 
inhibit ALDH2 activity to 61.4% of wild type but not as good as DEAB. Daidzin 
could not block ALDH2 activity in our a. It might be due to cell line specificity. 
DEAB were chosen for its best inhibiting effect on ALDH2 activity. 
 
4.2.5 Localization of fluorescent probes 
To test the localization of RSAAA and RSACOOH, a co-staining experiment 
was performed using LysoTracker or MitoTracker with these two dyes. Both 
RSAAA and RSACOOH came into the cells and stained the specific subcellular 
loci. Overlay of two staining channels showed that staining from both dyes were co-
localized with MitoTracker (Fig. 4.10) but not with LysoTracker (Fig. 4.11). The 
results from staining was consistent with our initial design that these probes could 
preferentially target mitochondria. 
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Figure 4.9. Inhibitors of ALDH2. (a) Structures of different inhibitors. (b) The ALDH2 inhibition effect of different inhibitors. The 
concentration of inhibitors were chosen according to the previous research [137, 158, 159]. Experiment was only performed once and 
further repeating experiments were needed for statistically analysis.  
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Figure 4.10. Cell co-staining of organic probes and MitoTracker. Cells were stained with either RSAAA or RSACOOH for 0.5 h in 
the presence of MitoTracker. Cy3 channel tracked organic probes while GFP showed the staining from MitoTracker. DAPI channel 
was for dead cells staining. Overlay of three channels indicated both RSAAA and RSACOOH co-localized well with MitoTracker. 
Scale bar: 10 µm.  
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Figure 4.11. Cell co-staining of organic probes and LysoTracker. Cells were stained with either RSAAA or RSACOOH for 0.5 h in 
the presence of LysoTracker. Cy3 channel tracked staining of organic probes. GFP showed the staining from LysoTracker. DAPI 
channel were was for dead cells staining. Overlay of three channels indicated both RSAAA and RSACOOH staining not co-localized 
well with LysoTracker. 
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4.2.6 DEAB change the fluorescence of cells stained with RSAAA 
In Aldefluor Assay, inhibitor treatment should lead to the decrease of 
fluorescent intensity in cell population which possessed higher ALDH activity. To 
test whether the designed assay could change the fluorescence, flow cytometry was 
performed on -/+ DEAB group stained with either RSAAA or RSACOOH. As we 
expected, treatment with 15 µM DEAB (Fig. 4.12) increased the fluorescence 
intensity of RSAAA group (from 5141 to 8980) but not RSACOOH (from 482 to 
473). This was because DEAB inhibited the ALDH2 activity in cells, which led to 
the accumulation of RSAAA inside cells. This experiment further confirmed the 
hypothesis that RSAAA was oxidized by ALDH2 and was converted to RSACOOH, 
which could be rapidly pumped out of cells. 
 
4.2.7 Isolation of population with different fluorescent intensity and assays for their 
tumorigenicity 
After the selections of substrate and inhibitor, we planned to use this method 
(we named it AAA assay after the name of the fluorescence probe RSAAA) to 
isolate ALDH2 high population. In order to mimic Aldefluor assay, two parallel 
experiments -/+ DEAB were performed. Two gates were set up according to the 
flow cytometry of + DEAB group in the FACS assay (Fig. 4.13) to isolate three 
subsets: “Fluo Low”, “Fluo Medium” and “Fluo High” in the -DEAB group. “Fluo 
Low” was about 1% of the total population with the lowest fluorescence. “Fluo 
High” was about 5-7% of the total population with the highest fluorescence. “Fluo 
Medium” was chosen for the middle 40% of “Fluo Low” and “Fluo High”.   
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Figure 4.12. Fluorescent intensity changed upon DEAB treatment. a) Cells were treated 
with or without DEAB and then stained separately either with RSAAA or with 
RSACOOH. b) Quantification of fluorescence in figure a). Experiment was only 
performed once. Further repeated experiments were needed for statistically analysis. 
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Figure 4.13. Gating of “Fluo Low”, “Fluo Medium” and “Fluo High” population. “Fluo 
Low” was around 1% of total population with the lowest fluorescence signals for DEAB 
positive group. “Fluo High” was around 5-7% of total population with the highest 
fluorescence signals for DEAB positive group. “Fluo Medium” was around 10% of total 
population between “Fluo Low” and “Fluo High” for DEAB positive group. In DEAB 
negative group, the corresponding “Fluo Low”, “Fluo Medium” and “Fluo High” were 
10%, 10% and 5% of the total population. 
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In this case, the cell percentage for three subsets in –DEAB group turned to be around 
10%, 40% and 5%. Because the sensitivity of flow cytometry, the total population should 
not be 100% to optimize the clear isolation of different subsets, especially the “Fluo 
Low” and “Fluo High” subsets.  
To check the tumorigenicity of the “Fluo Low”, “Fluo Medium” and “Fluo High” 
subsets, three different assays were performed to check the potential of being cancer stem 
cells (Fig. 4.14): sphere assay, soft agar assay and gene expression assay. The first two 
experiments tested the tumorigenicity potentials in 2D and 3D environment. The gene 
expression assay by QRT-PCR provided information on important markers indicating 
cancer stem cells.  
We found that “Fluo Low” “Fluo Medium” and “Fluo High” populations each 
formed 45.3±4.9, 27.5±10.6 and 32.7±4.6 spheres, respectively. For Soft agar assay, 
they each developed 980±51.3, 1174.7±72.2 and 610±2 colonies. As we can see, 
“Fluo Low” subsets can form more spheres (Fig. 4.14.a) and colonies (Fig. 4.14.b) than 
“Fluo High” group. “Fluo Medium” can form more colonies than “Fluo Low” group. No 
significant difference was found in the potency to form spheres between “Fluo Low” and 
“Flow Medium” group. “Fluo High” seemed to have lowest potency to form tumor, 
however the “Fluo Low” and “Fluo Medium” might have comparable tumorigenicity. 
Statistically analysis were performed using student t test with a 95% confidence interval. 
Five genes were chosen for the gene expression analysis, Nanog [160], OCT4 [160, 
161], ALDH1 [140], Dclk1 [162] and ALDH2. The first four were reported as markers for 
colon cancer stem cells. 
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Figure 4.14. Tumorgenicity of AAA sorting populations. a) Sphere assay and b) Soft agar assay were performed to those populations 
gated by DEAB treatment. Star indicated significant difference by student t test with a 95% confidence interval. Double star indicated 
the p-value in student t-test is less than 0.001. “Fluo Low” population had higher number of spheres and colonies compared to “Fluo 
High”. ALDH2 activity might be correlated with tumorgenecity of cell lines. 
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Figure 4.15. Cancer stem cell marker expression in AAA assay sorting populations. Four 
different cancer stem cells markers’ expressions were analyzed using the 2 –ΔΔCT method 
[157] for relative quantification. Star indicated significant difference by student t test 
with a 95% confidence interval.  
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Three out of four cancer stem cell marker genes expressions were 
significantly higher in “Fluo low” group: Nanog, OCT4 and ALDH1 (Fig. 4.15) by 
student t-test with a 95% confidence interval. The colon cancer stem cell marker 
Dclk1 did not show significantly difference among three populations. Interestingly, 
no differences were observed for ALDH2 expression. Thus the difference in 
ALDH2 activity might be due to different activation state of expressed ALDH2 
proteins. From the results of the three tumorigenicity experiments, “Fluo Low”, 
which indicated “high ALDH2 activity” group, might have a higher proportion of 
cancer stem cells compared to the “Fluo High” group that was the cells with “low 
ALDH2 activity”. We could use this method to isolate cancer stem cells that had a 
higher ALDH2 activity in colon cancer cells. 
 
4.3 Conclusion 
In order to isolate populations with higher ALDH2 activity in colon cancer, we 
have synthesized specific fluorescent probes and designed a protocol mimicking 
Aldefluor Assay. With a positive charge on the backbone, the fluorescent probes 
RSAAA could be directed to mitochondrion specifically [163]. Since ALDH2 is the 
major member of ALDH family in mitochondria, the RSAAA could be oxidized and 
converted to RSACOOH by ALDH2. As the oxidative product of RSAAA, 
RSACOOH was also synthesized as a staining control. The retentions of RSAAA 
and RSACOOH were not the same inside cells. Fluorescence chase experiments 
confirmed RSACOOH was pumped out of cells immediately (less than 20 minutes), 
while RSAAA staining kept at least 30% fluorescence for up to 2 hours. This 
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experiment supported the hypothesis that once oxidized by ALDH2, RSAAA could be 
converted to RSACOOH and pumped out of cells.  
These two organic dyes were then tested for their potentials as substrates for 
ALDH2. Only RSAAA could be oxidized by ALDH2 in the in vitro activity assay. Cell 
imaging from confocal microscope confirmed the localizations of RSAAA and 
RSACOOH were mainly in mitochondria. Under the treatment of ALDH2 inhibitor, 
DEAB, the fluorescence inside cells significantly increased, which further supported our 
hypothesis. Using DEAB treatment to gate for “Fluo Low”, “ Flow Medium” and “Flow 
High” population, cell populations with different fluorescent signals were isolated from 
DEAB negative group. Tumorigenicity experiments on those three populations showed 
ALDH2 high group (“Fluo low” group) had a higher potential for tumor formation 
compared to the other two groups. 
In conclusion, an assay to assess ALDH2 activity in live colon cancer cells was 
developed using the organic fluorescent probes synthesized in our lab. Higher ALDH2 
activity might be correlated with higher tumorigenicity. This assay might be applied to 
the isolation of cancer stem cells.  
 
4.4 Experimental Section 
4.4.1 Cell maintenance 
Please refer to Chapter 1 for HCT116 and HCT15 maintenance. The SW620 cell 
line was a kindly gift from Prof. Franklin G. Berger (University of South Carolina, 
Center for Colon Cancer Research). SW620 cells were maintained in RPMI1640 medium 
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with 10% FBS. All cells were in a water-saturated atmosphere of 5% CO2 and 95% 
air at 37°C. 
 
4.4.2 ALDH2 activity assay 
Around 5 × 106 cells were trypsinized and washed twice with PBS. Cells were 
lysed with 1% Triton X-100 in potassium phosphate buffer [50 mM (pH 7.4)] 
containing a complete EDTA-free protease inhibitor cocktail (Roche Diagnositic). 
Cell debris was removed by centrifugation and protein content was determined with 
the Commassie Blue Kit from Thermo Scientific. The reaction mixture contained 40 
mM (pH 7.4) potassium phosphate buffer, 4 mM dithiothreitol, 5 mM MgCl2, 10 
mM 4-methyl-pyrazole, 0.8 mM β-nicotinamide adenine dinucleotide (β-NAD+) 
and 100 μg of total protein. The reaction was initiated with the addition of 14 µM 
propionaldehyde and production of NADH was measured at 340 nm over time. The 
specific activity was expressed as nmol of NADH/min/mg of protein. 
 
4.4.3 Cell imaging 
Confocal fluorescence imaging was performed with an Olympus X81 
fluorescence microscope. Cells were incubated with sensors and trackers in the 
presence of (+/-)-Verapamil Hydrochloride (from MP Biomedicals, Cat. No: 
195545) for 0.5 hour at 37°C. Fluorescence images of cells were taken after washed 
with PBS buffer. 
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4.4.4 Flow cytometry 
Cellular ALDH2 activity was quantified by flow cytometric analysis. HCT15 cells 
were seed on 10 cm plates to allow adhere and grow overnight. Cells were trypsinized the 
next day and 1 × 106 cells were collected for each sample. After washed once with PBS, 
cells were stained with indicated dyes for 0.5 hour at 37°C. The samples were washed 
once with cold PBS and resuspended in PBS + 0.1% FBS. Samples were analyzed by BD 
LSRII flow cytometer (BD Bioscience). For DEAB treatment group, DEAB was in the 
staining buffer and washing buffers for each step.  
 
4.4.5 Cell sorting 
To get enough populations, 2 × 107 cells were collected for each sample and 
subjected to sort by BD FACS Canto I (BD Bioscinece). Cells were sorted according to 
the gates set up by DEAB treatment group. Sorted cells were kept in full medium on ice 
for the next steps.  
 
4.4.6 Mammal sphere assay 
Sorted cells were washed once with PBS and resuspended in mammal sphere culture 
medium (Serum-free DMEM/F12 (Invitrogen) and supplemented with 20 ng/mL 
epidermal growth factor (Stemgent, Inc.), 10 ng/mL basic fibroblast growth factor 
(Stemgent, Inc.), 10 μg/mL insulin (Sigma), 1× B27 supplement (Invitrogen), 100 U/mL 
penicillin, 100 μg/mL streptomycin and 0.5% bovine serum albumin (Sigma)). Cells were 
seeded in 1% agarose pre-coated 12 well plate at density of 10000 cells/mL. Cells were 
cultured in 5% CO2 at 37 °C for a week. Spheres of more than 20 cells were counted 
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under Olympus X51 microscope. Each experiment was performed in triplicate. Error 
bars represented ± standard deviation. 
 
4.4.7 Soft agar assay 
Sorted cells were washed with PBS once and 5000 cells from each sample were 
seeded in one well of 6-well plate in 0.3% low melting point agarose (Invitrogen) 
with culture medium on top of solidified 0.5% low-melting point agarose with 
culture medium. Cells were cultured in CO2 and 95% air at 37°C for two weeks and 
1 mL of 0.005% crystal violet was added to visualize the colonies before counting. 
Colonies were counted by naked eye. Images of soft agar assay were obtained by gel 
imaging system GelDoc XR (Bio-Rad). Each experiment was performed in 
triplicate. Error bars represent ± standard deviation. 
 
4.4.7 Gene expression analysis 
QRT-PCR was used to evaluate gene expression level by measuring relative 
quantity of mRNA of each gene. Total RNA was extracted from the cells using 
RNeasy mini purification kit according to manufacturer’s protocol (Qiagen), and 
subsequently reverse-transcribed with a qSCript cDNA synthesis kit (Quanta 
Biosciences). RT-qPCR (iQ5 real-time PCR detection system, Bio-Rad) was done 
by the method described as: 45 cycles of PCR (95 °C for 15 s, 60 °C for 15 s, and 
72 °C for 30s), after initial denaturation step of 5 minutes at 95 C , by using 12.5 
µL of iQ5 SYBR Green I supermix, 2 pmol/µL of each forward and reverse primers 
and 0.5 µL cDNA templates in a final reaction volume of 25 µL. Data collection 
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was enabled at 72 C in each cycle and CT (threshold cycle) values were calculated using 
the iQ5 optical system software version 2.1. The primers used for RT-qPCR are showed 
in Table 4.2. The primers were reported previously in literatures [160] or designed by our 
lab. Data analysis was performed using the 2 –ΔΔCT method [157] for relative 
quantification. The primers were then synthesized commercially (Integrated DNA 
Technologies, Inc.), and evaluated for an annealing temperature of 60˚C. All samples 
were normalized to Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as the house 
keeping gene. Each experiment was performed in triplicate. Error bars represent ± 
standard deviation. 
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Table 4.2. Primers of cancer stem cell markers 
Primer name Gene name Specie Sequence 
OCT4 F OCT4 HUMAN CCGTGAAGCTGGAGAAGGAGAAG 
OCT4 R OCT4 HUMAN AGCGGCAGATGGTCGTTTGG 
Nanog F NANOG HUMAN GAACTCTCCAACATCCTGAACCTC 
Nanog R NANOG HUMAN CCTTCTGCGTCACACCATTGC 
ALDH1 F ALDH1 HUMAN AGCAGGAGTGTTTACCAAAGA 
ALDH1 R ALDH1 HUMAN CCCAGTTCTCTTCCATTTCCAG 
ALDH2 F ALDH2 HUMAN ACAAGGAAGATGTGGACAAGG 
ALDH2 R ALDH2 HUMAN ATGGTCCTCAAATGTCTCCG 
Dclk1 F Dclk1 HUMAN TGATGCTGTTGGTCGATGTAG 
Dclk1 R Dclk1 HUMAN AGTGCTATGACAGAAACTCCAG 
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